 
1 
Protocol #13P.528, 
v5.4(13September 2017) THOMAS JEFFER SON UNIVERSIT Y 
Kimmel Cancer Center  
 
PHASE I STUDY OF ALISERTIB WITH CONCURRENT FRACTIONATED 
STEREOTACT IC RADIATION TR EATMENT  FOR RECURRENT HIGH GRADE 
GLIOMAS 
 
Principal Investigators: Wenyin Shi, MD, PhD  
Department of Radiation On cology 
[ADDRESS_1007584], Suite G301 
Philadelphia, PA [ZIP_CODE] ([PHONE_15328] Fax: ([PHONE_15329] 
Co-Principal 
Investigator: [INVESTIGATOR_737567], MD 
Rani Anne , MD Voi chita 
Bar-Ad, MD Ad am 
Dicker, MD James 
Evans, MD Ch ristopher 
Farrell, MD Jon Glass, 
MD 
Kevin Judy , MD 
Lyndon Kim, MD  Maria Werner-Wasik, M D  
Nina Martinez, MD  
 Funding Sponsor: Millennium 
Regulatory Sponsor: Thomas Jefferson University 
IND Number: [ADDRESS_1007585]: Alisertib 
Protocol Number: Jefftrial# 3007  
CCRRC# 201 2-12 
IRB# 13P.528 
 
Version: Date: 
1.0 9/16/2013 
3.0 2/17/2014 
4.0.1 9/03/2014 
5.0 4/16/2015  
5.1 02/16/2016  
5.2 07/20/2016  
5.3 08/08/2017  
5.4 9/13/2017  
 
 
2 
Protocol #13P.528, 
v5.4(13September 2017) CONFIDENTIAL  
This documen t is confidential and the prop erty of THOMAS JEFFERSON 
UNIVERSITY.  No part of it may be tr ansmitted, reprodu ced, published, or used by 
[CONTACT_737596]. 
 
 
3 
Protocol #13P.528, 
v5.4(13September 2017) [ADDRESS_1007586] SELECTION AND WITHDRAWAL......................................................................................... .20 
 4.1 INCLUSION CRITERIA............................................................................................................................. ....20 
 4.2 EXCLUSION CRITERIA ............................................................................................................................. ..20 
 4.3 GENDER/MINORITY/PEDIATRIC INCLUSION FOR RESEARCH..................................................................... .[ADDRESS_1007587] RECRUITMENT AND SCREENING ................................................................................................ .21 
 4.5 EARLY WITHDRAWAL OF SUBJECTS ......................................................................................................... .22 
 4.5.1 When and How to Withdraw Subjects ................................................................................................. .22 
 4.5.2 Data Collection and Follow-up for Withdrawn Subjects .................................................................... .22 
5 STU 
5.1 Y DRUG/THERAPY ............................................................................................................................ .22 
DESCRIPTION ............................................................................................................................. ............... .22 
 5.2 TREATMENT REGIMEN ............................................................................................................................. .22 
 5.3 RISKS ............................................................................................................................. .......................... .23 
 5.4 METHOD FOR ASSIGNING SUBJECTS TO TREATMENT GROUPS ................................................................. .24 
 5.5 PREPARATION AND ADMINISTRATION OF STUDY DRUG/THERAPY ........................................................... .[ADDRESS_1007588] COMPLIANCE MONITORING ....................................................................................................... .24 
 5.7 PRIOR AND CONCOMITANT THERAPY ....................................................................................................... .24 
 5.8 PACKAGING ............................................................................................................................. ................. .25 
 5.9 BLINDING OF STUDY DRUG ...................................................................................................................... .25 
 5.10 RECEIVING, STORAGE, DISPENSING AND RETURN .................................................................................... .25 
 5.10.1 Receipt of Drug Supplies .................................................................................................................... .25 
 5.10.2 Storage ............................................................................................................................. ................... .25 
 5.10.3 Dispensing of Study Drug ................................................................................................................... .25 
 5.10.4 Return or Destruction of Study Drug .................................................................................................. .25 
6 STUD Y PROCEDURES............................................................................................................................. .....26 
 Table of Contents 
STUDY SUMMARY ...................................................................................................................................................7  
1 INTR 
1.1 ODUCTION............................................................................................................................. ...............10 
SPECIFIC AIMS AND HYPOTHESIS ............................................................................................................. .11 
 1.1.1 Hypothesis ............................................................................................................................. ..............11 
 1.1.2 Primary Aims ............................................................................................................................. ..........11 
 1.1.3 Secondary Aims ............................................................................................... ................................... .11 
 1.2 BACKGROUND ............................................................................................................................. ..............11 
 1.2.1 Recurrent Glioma ............................................................................................................................. ...11 
 1.2.2 Fractionated Stereotactic Radiation Therapy (FSRT) ........................................................................ .12 
 1.2.3 Aurora A Kinase and Aurora A Kinase Inhibitor Alisertib (MLN8237) ............................................. .[ADDRESS_1007589] ............................................................................................................................. ..................... .14 
 1.3.2 Aisertib Treatment ............................................................................................................................. ..15 
 1.4 PRECLINICAL DATA............................................................................................................................. ......15 
 1.4.1 In Vitro Studies ............................................................................................................................. ......15 
 1.4.2 In Vivo Studies .................................................................................................. .................................. .16 
 1.5 CLINICAL DATA TO DATE......................................................................................................................... .17 
 1.6 DOSE RATIONALE AND RISK/BENEFITS .................................................................................................... .18 
2 STUDY OBJECTIVES .................................................................................................................................... 19 
2.1 PRIMARY OBJECTIVE ................................................................................................................................. 19 
2.2 SECONDARY OBJECTIVE(S) ....................................................................................................................... 19 
 
 
  
 
  
 
  
 
  
 
 
D 
 
 
  
 
  
 
  
 
  
 
  
 
6.1 S
TUDY VISIT SCHEDULE ............................................................................................................................ 26 
6.2 D EFINITION OF DOSE LIMITING TOXICITIES .............................................................................................. 26 
6.3 D OSE DELAYS AND DOSE MODIFICATIONS . ..............................................................................................27 
 
 
4 
Protocol #13P.528, 
v5.4(13September 2017)  6.[ADDRESS_1007590] POPULATION(S) FOR ANALYSIS ................................................................................................. .30 
8 SAFETY AND ADVER SE EVENTS ............................................................................................................. 30 
8.1 D EFINITIONS.............................................................................................................................................. 30 
8.2 RECORDING OF ADVERSE EVENTS............................................................................................................. 32 
8.3 U NBLINDING PROCEDURES........................................................................................................................ 33 
8.4 STOPPI[INVESTIGATOR_16442] ....................................................................................................................................... 33 
8.5 D ATA AND SAFETY MONITOR ING PLAN .................................................................................................... 33 
8.5.1 Medical Monitoring and AE/SAE Reporting ....................................................................................... [ADDRESS_1007591] STIPENDS OR PAYMENTS ............................................................................................................ 40 
13 PUBLICATION PLAN .................................................................................................................................... 40 
14 REFERENCES  ................................................................................................................................................. 40 
15 APPENDIX ....................................................................................................................................................... 43 
 
 
5 
Protocol #13P.528, 
v5.4(13September 2017) AE adverse event 
ALT alanine aminotransferase/glutamic pyruvic transaminase/GPT 
ANC absolute neutrophil count 
ASCO American Society of Clinical Oncologists 
AST aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT 
AUC area under the curve 
BUN blood urea nitrogen 
CIS carcinoma in-situ 
Cmax maximum concentration of drug 
CNS central nervous system 
CR complete response/remission 
CTCAE NCI common terminology criteria for adverse events 
CV coefficient of variation 
DLT dose-limiting toxicity 
DNA deoxyribose nucleic acid 
ECG 12 lead el ectrocardiogram 
ECOG Eastern Cooperative Oncology Group 
FDA food and drug administration 
GBM Glioblastoma 
Gy Gray (unit of radiation) 
H3, H4 histones H3, H4 
HIV human immunodeficiency virus 
i.v. intravenous(ly) 
IRB institutional review board 
LLN lower limit of normal 
LVEF left ventricular ejection fraction 
mg/m2 milligrams per square meter 
MTD maximum tolerated dose 
MUGA multiple uptake gated acquisition scan 
MWF monday, wednesday, Friday 
NCI national cancer institute 
NHL non-hodgkin’s lymphoma 
NIH national institutes of health 
PD Pharmacodynamic 
P-gp p-glycoprotein 
PK Pharmacokinetic 
PLT Platelet 
PR partial response 
SAE serious adverse event 
QoL Quality of life 
SD stable disease 
FSRT Fractionated stereotactic radiation therapy 
T4 Thyroxine 
TSH thyroid stimulating hormone 
 List of Abbreviations  
 
 
6 
Protocol #13P.528, v5.24(13September 2017)  
 
 
 
ULN upper limit of normal 
WBC white blood cell 
WNL within normal limits 
WOCBP  women of childbearing potential 
 

 
7 
Protocol #13P.528, v5.24(13September 2017) Study Summary  
 
Title Phase I study of Alisertib with concurrent fractionated stereotactic radiation 
treatment for recurrent high grade gliomas 
Short Title Safety study of Alisertib and radiation for  recurrent glioma 
 
Protocol Number JeffTrial# 3007 
CCRRC#  2013-12 
IRB# 13P.528 
Phase 1 
 
Methodology/Stu 
dy Design This is an open label phase I clinical trial. Alisertib will be administered 
twice daily by [CONTACT_442550] s of radiation treatment. The ra diation dose and 
fractionation a re pre-determined. Alisertib dose will escalate according to 
the protocol. Th ere is no intra-patient dose escalation. 
Study Duration 18 months 
Study Center(s) Single-center. 
 
 
  
 
  
Objectives Primary Objectives: 
1.   Evaluate the safety and tole rability of the study treatment 
2.   To de termine the Ma ximum Tolera ted Dose (MTD) of Alisertib 
when combined with fractiona ted stereotactic radiation tr eatment for 
recurrent high grade gli oma. 
 
Secondary Objec tives: 
1.   To estimate [ADDRESS_1007592] on quality of life (QoL) 
Number of 
Subjects  
Up to 24 subj ects 
 
 
8 
Protocol #13P.528, v5.4 
(13September 2017)  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
Diagnosis and 
Main Inclusion 
Criteria Patients with r ecurrent high grade gli oma (grade III or IV). 
Main inclusion crite ria: 
1. Patients must have a previously histolog ically or cytolog ically 
confirmed high grade gli oma (astrocytic or oligodendroglia l 
supratentorial tumors grade 3 or 4) that h as been previously tr eated 
with fractionated radiation the rapy and no w shows evidence o f 
recurrence. 
2. Patients must have recovered f rom the to xic effects of prior therapy. 
3. Patients must have recovered from the effec ts of surgery.  There must 
be a minimum of [ADDRESS_1007593] a 2-week break be tween prior treatment and 
the protocol treatment. 
5. Prior treatment with fractionated radiation therapy (up to 60Gy) is an 
eligibility criterion, howeve r there should not have been a second 
course of fractiona ted radiotherapy to the supratentoria l area. 
6. One prior single fraction radiosurg ical procedure within the treatment 
field is acceptable if V12<5 cc (V12 is the volume of n ormal brain 
(outside G TV) receiving 12 or more  Gy). Additional radiosurgical 
procedures outside of the treatment area a re acceptable. 
7. Subjec t must be able to take ora l medication and to mainta in a fast is 
required for 2 h ours before and 1 hour a fter MLN8237 administration. 
8. ANC > 1500/m m³, platelets > 100,000/mm³, Hgb > 9 g/dL. Va lues 
must be obtained without need for mye loid growth factor or pla telet 
transfusion support within 14 day s of registration. Howe ver, 
erythrocyte growth factor is allowed as per published ASCO 
guidelines. 
9. Total bilirubin ≤ UL N, SGOT (AST) and SGPT (ALT)< 1.5 x UL N, 
within 14 days of registration. 
10.  
clearance m -Gault), within 14 day s 
of registration. 
11.  Age >18 years. 
12.  ECOG performance status <2 (see Appendix I). 
13.  Life expectan cy of greater than [ADDRESS_1007594] agree to use adequat e 
contraception (hormonal or barrie r method of birth control; 
abstinence) pri or to study entry and for [ADDRESS_1007595] dose.  
16.  Ability to unde rstand and the willingne ss to sign a writ ten informed 
consent document. 
 

 
9 
Protocol #13P.528, v5.4 
(13September 2017) Study Therapy, 
Dose, Route, 
Regimen  
Alisertib (MLN8237) wi ll be administered by [CONTACT_1966], twice daily. The dose 
of Alisertib will be de fined by [CONTACT_760]. 
Duration of 
administration 
and follow-up Concurrent with radiation treatment, then 30 days after finishing radiation 
therapy will receive twice daily from day 1-7, ever y 21 day cycle for up to 
18 cycles, or until tumor progression. 
Reference 
therapy  
None. This is a phase I study 
 
 
  
 
  
 
Statistical 
Methodology We will use a two-stage accrual design at each dose considered. We will 
initially enter 3 subjects at each dose. I f none of the three expe riences a dose-
limiting toxicity we will proceed to the next dose. I f one of the three 
experiences toxicity at that level, we will accrue 3 more subjects at that dose. 
If at any time there are two or more  dose-limiting toxicities (in the 3-6 
subjects) on a given dose , we will terminate accrual to the Phase I portion of 
that trial. No patie nt will be treated  at a higher dose until the [ADDRESS_1007596] comple ted their toxicity evaluation period at the current dose. With thi s 
plan, a dose with a 50% or gr eater probability of causing a dose-limiti ng 
toxicity has at most a 12.5% chance of s atisfying the conditions for dose 
escalation after the first [ADDRESS_1007597] a 50% chance of stoppi[INVESTIGATOR_25577] 
3. With the two- stages (3-6) togeth er, there is at most a 17.2% chance of 
escalation. 
 
  
  
 
  
 
  
Schema  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
10 
Protocol #13P.528, v5.4 
(13September 2017) 1.[ADDRESS_1007598] ice (FDA Title 21 part 312 and 
International Confe rence on Harmonization guidelines), applicable governme nt regulations and 
Institutional research policies and procedure s. 
 
1.[ADDRESS_1007599] common primary bra in tumors in adults [1]. The standard of care 
for newly diagnosed high grade glioma, esp ecially glioblastoma mu ltiforme (GBM), is maximal 
surgical resection, followed by [CONTACT_54615] t reatment (RT) and concurrent and adjuvant 
chemotherapy with temozolamide (TMZ) [2]. Nonetheless, 90% of the patients recur within 2 
years [2, 3]. There is no standa rd treatment for r ecurrent high g rade glioma. Therapeutic options 
include re peat  surgery, re-irradiation, cy totoxic agents, and targe t therapi[INVESTIGATOR_014]. Fractionated 
stereotactic radiotherapy (FS RT) may offe r some improvement in su rvival with minimal toxicity 
for patients with previously treated gliomas. Our insti tution published one of the la rgest single 
institution expe riences of using FS RT in recurrent high grade glioma. The tr eatment is well 
tolerated with a favorable medi an survival of 11 months af ter FSRT. Aurora kinase A is 
overexpre ssed in many malignant tumors [4]. Overexpression of Au rora-A ha s a prognostic va lue 
in high grade glioma. Administration of Au rora-A kinase inhibitor can suppre ss the growth of 
GBM, as well as be synergistic to radiation treatment [5-8]. Alisertib (MLN8237) is a potent 
second generation Aurora- A kinase inhibitor [4, 9, 10]. Combining FS RT with Alisertib for patients 
with recurrent high glio ma likely would result in improved local control and prolonged survival. 
The effect of combination the rapy may be mo re than addit ive effect, as suggested by a 
preclinica l st udy [7]. The current pha se I study will assess the safety p rofile of combining 
different doses of Alisertib with FSRT. We will determine the MTD (maximum tole rated dose), 
as well as a recommende d phase II trial dose of Alisertib when used concurrently with radiation 
treatment for recur rent glioma patients. 
 
1.1.2 Primary Aims:  
• Evaluate the safety and tole rability of the study treatment 
• To determine the M aximum Tolera ted Dose (MTD) of Alisertib when combined with 
fractionated stereotactic ra diation treatment for recurrent high grade gli oma. 
 
1.1.3 Secondary Aims: 
• To estimate 6 month progre ssion free surviva l rate 
• To estimate the median time to prog ression 
• To estimate ove rall survival 
• To estimate the impact on quality of life (QoL) 
 
1.[ADDRESS_1007600] frequent primary brain tumor s een in adults. The addition of 
temozolomide (concurrent and adjuvant) to radiation the rapy in the upfront setting improved 
overall survival in a phase III trial from 12.1 to 14.6 months [2, 3]. Nonetheless, following 
radiation therapy, 90% of gli omas recur within 2 years. The aggressive nature of gliomas is 
 
 
11 
Protocol #13P.528, v5.4 
(13September 2017)  
 
 
 
explained in terms of inappropria te activation of pro-surviva l pathways (esp. PI3 Kinase) [11, 12], 
aberrant DNA repa ir [13], promine nt angiogenesis [14], and multiple aberrations in the epi[INVESTIGATOR_737568] [15]. 
 
Gliomas frequently recur close to their site of origin, making re- treatment challenging ; 
furthermore, gliomas become more aggressive over time [16-18]. Continued tumor growth 
produces neurol ogical symptoms and eventual death. Poor pro gnostic factors include inc reased 
age, lower Ka rnofsky performance score (KPS), initial and on-study histolog ies of glioblastoma 
multiforme (GBM), corticosteroid use, shorte r time from original diagnosis to r ecurrence, and 
tumor outside fronta l lobe [19]. Overall survival for relapsed glioma is less than [ADDRESS_1007601] treatment for recurrent t umor; therapeutic options include re peat surgery [20- 
22], re-irradiation [23-29], cytotoxic agents [30-32] and anti-angiogenic therapy [33-37]. Bevacizumab is 
an FDA approved agent for recur rent glioma that produces a response ra te of 30-40% and a 
median overall survival of 9 months [38]. Unfortunately, there is emerging evidence that tu mors 
that progress on bev acizumab a re extremely resistant to other therapi[INVESTIGATOR_118473] [39], suggesting 
that bevacizumab may be be st reserved for after other modalities have b een exhausted. 
 
1.2.2 Fractionated S tereotactic Rad iation Th erapy (FRST) 
Radiation therapy is thought to kil l living cells through the induction of D NA damage, in 
particular DNA doubl e strand breaks. Due to  a variety of practical and technical reasons, no rmal 
tissue is oft en incorporated into the ‘ target volume ’. Early radiotherapi[INVESTIGATOR_541] s discovered that 
fractionating the treatment (i.e. delivering it in many small daily doses over a number of weeks) 
is a way of damaging tumor tissue mo re than nor mal tissues. In stereotactic ra diosurgery (SRS ) 
on the other hand, a large dose of ra diation is delivered in a sing le session to a ste reotactically 
defined intracranial volu me. SRS avoids tox icity by [CONTACT_737597] t 
definition, thus avoidi ng radiating normal structures. 
 
Fractionated stereotactic radiotherapy combine s the precis ion of stereotactic positioning with the 
radiobiolog ic advantage of fractionation. FS RT, as utilized in this t rial, utilizes a frameless mask 
system with d aily stereotactic images for precise localization. FSRT is delivered by a Nov alis 
LINAC based telethe rapy unit. 
 
The Jefferson FSRT program is headed by [INVESTIGATOR_124]. David Andre ws, a pi[INVESTIGATOR_737569]. 
Neurosurgeons, Radiation oncolog ists and neuro-oncolog ists work closely to gether to obtain 
consensus treatment d ecisions. Following the acquisition of CT and contra st enhanced MR I 
images (obtained with face mask in place ) treatment is planned by a dedicated tea m of physicists 
and therapi[INVESTIGATOR_11437]. 
 
Early Jefferson expe rience determined that re-irrad iation with FS RT was extremely well 
tolerated in recurrent glio ma; there were no ≥ grade 3 tox icities in 20 patien ts [23]. Gross tumor 
volume (GTV) was defined by [CONTACT_737598]-enhanced tumor ed ge using T1 we ighted series. 
The PTV was considered equivalent to the GTV and ede ma was not included in the t reatment 
volume. Tumors we re treated to the 85-90% isodo se line and cove rage of the target volume was 
reviewed on the planning sy stem. 
 

 
12 
Protocol #13P.528, v5.4 
(13September 2017) 
A report on 147 patients with recurrent high g rade gliomas (Grade 3 astroctoma or GBM) 
undergoing this treatment between 1994 and 2008 wa s recently publi shed in the Journa l of 
Clinical Oncology [29]. The medi an age at primary diagnosis was 53 ye ars (range, 19 to 86 
years). Sixty-seven pat ients (45%) were female. At initial diagnosis, 105 patients (71% ) were 
diagnosed with GBM and 42 we re diagnose d with anaplastic astrocytoma. All patients r eceived 
initial postoperative confor mal fractionated RT to a mean and median dose of 60.0 Gy in daily 
2.0 Gy fractions. Eighty-four patients (60% ) had surgica l resection of their progressive glioma 
prior to salv age FSRT. Forty-eight of the 147 patients received various che motherapy agents 
(mostly temozolomide) at recurrence together with FSRT. 
 
Toxicity was minimal; no patients demonstra ted clinically significant acute morb idity and all 
patients we re able to com plete the prescribed radiation dose without in terruption. No patient 
required hospi[INVESTIGATOR_737570]. 
 
The median time from diagnosis to H-S RT was 8 months ( range 4-205 mo). Median survival ti me 
from the sta rt of FSRT was 10 months (8, 12 mo) for patie nts with grade 3 tumor s and 11 months 
(9, 14) in grade 4 patients. Three month follow up MRI scans following H-SRT indi cated stable  
disease in 89 (60% ). Minimal response a s defined by [CONTACT_737599] 15 (10% ) 
patients and progre ssion was noted in 43 (3 0%) patients. 
 
The University of Heidelberg has published their expe rience of re-irra diation for recurrent 
gliomas in [ADDRESS_1007602] surviva l 
(survival from re-irradiation for gr ade 3 and 4 patients was 16 months and 8 months 
respectively ). Th e largest series of re-irradiation of recurrent gli omas examined 172 patie nts with 
recurrent gliomas of wh ich 111 had high-grade gl iomas [24]. Fractiona ted stereotactic ra diation 
therapy was performed with a medi an dose of [ADDRESS_1007603] notably age ( median age was 41 
versus 53 in this report). 
 
The best reported surviva l for stand ard fractionate d re-irradiation combined with chemotherapy 
was reported by [CONTACT_737600] [40]. Thirty-one patients received ex ternal beam RT to a dose of 
34.5 Gy with concurrent lumustine (CCNU)  and reported a 13.5-month MS T after re-irradiation. 
Other studies combi ning re-irradiation with chemothe rapy have demonstrated simi lar results [24, 
40, 41]. 
 
1.2.3 Aurora A Kin ases and the Aurura A  Kinase Inhibitor Alisertib (MLN8237)  
Alisertib is a selective small molecule inhibitor of Au rora A kin ase that is being developed for 
the treatment of advanced malignanc ies. Aurora A kinase belongs to a highly conse rved family 
 
 
13 
Protocol #13P.528, v5.4 
(13September 2017) 
of serine/threonine protein kinase s that also includ es Aurora B and Aurora C. Aurora A and 
Aurora B are expressed in all actively dividing cells, while Au rora C expression is la rgely 
restricted to dividi ng germ cells [42]. Aurora A localizes to centrosomes and the proxima l mitotic 
spi[INVESTIGATOR_737571] s where it functions in a dive rse set of mitotic processes. 
 
The evidence supportin g Aurora A kinase as a therapeutic ta rget for the treatment of 
malignanc ies comes from several sour ces. First, the Aurora A kin ase gene is amplified  and/or 
overexpre ssed in many tumors, including colon, breast, panc reatic, and bladde r cancers, as well 
as certain lymphomas, leukemias, and mye loma [43-47]. Aurora A ov erexpression in human 
cancers has been correlated with increased aneuploidy and centrosome a mplification [48]. Second, 
forced overexpre ssion of Au rora A kinase in experime ntal models r esults in the tr ansformation 
of normal ce lls, sugge sting that Aurora A overexpression may be oncogenic [43]. Lastly, in a 
number of different expe rimental systems, Au rora A inhibition leads to mitotic delays and seve re 
chromosome alignment and segregation defects, followed by [CONTACT_283511]  [49-52]. Overall, the 
essential role of Au rora A in mitotic progression and it s dysregulation in ce rtain cancers makes it 
an attractive therapeutic ta rget. 
 
Given the obligatory role of mitosis  in tumor proliferation, an Aurora A inhibitor would be 
expected to have potentia l applications across a  broad range of human tumo rs, including GBM. 
Indeed, MLN8237 ha s demonstrated activity again st a variety of nonclinical solid tumor and 
hematological malignancy models g rown in vitro and in vivo [53, 54]. 
 
1.2.[ADDRESS_1007604] ic value in high g rade glioma. Administration of aurora kinase inhibit or 
can suppre ss the growth of glioblastoma model [8]. Moreover, inhibition of aurora- A kinase is 
found to syn ergize with r adiation in glioblastoma cells [55, 56]. Alisertib (MLN8237) is a second 
generation A URKA inhibitor and ha s recently entered phase I/ II clinical trials. Early clinica l 
studies showed promising result against mu ltiple types of cancers when used alone. Combinin g 
Alisertib with FS RT in patients with r ecurrent G BM likely would re sult in enhanced the rapeutic 
effects. T
he current phase I study will assess the safety profile of combining different doses of 
Alisertib with stand ard  dose FSRT in patients with r ecurrent GBM. We wi ll determine the MTD 
(maximum to lerated dose), as well as a recommended pha se II trial dose of Alisertib. 
 
 
14 
Protocol #13P.528, v5.4 
(13September 2017) 
1.3 Study Therapy 
1.3.1 FSRT 
Fractionated stereotactic surgery (FSRT) will be administered once daily, every weekday fo r a 
total of [ADDRESS_1007605] for radiation 
treatment planning . The gross tumor volume (GT V) will be de fined by [CONTACT_683941]-enhanced T1 
abnormality on the post-operative MRI scan. This wil l generally include the su rgical cavity 
margins from the most r ecent surgical procedure as well. There is no clinica l target vol ume 
(CTV) or planned target vol ume (PTV) expansion. 
 
All patients will r eceive 35 Gy in 3.5 Gy fractions. This dose maybe re duced to 30 Gy in 10 
fractions pe r the treating physician if the GTV is large (> 50 cc ) or close to critical structures 
(such as brainstem, opt ic nerves, or chias m). The dose is prescribed to the highe st isodose line 
that covers >99% of the GTV. 
 
1.3.[ADDRESS_1007606] radiation 
treatment. The dose o f Alisertib will be d etermined according to the p rotocol. 
 
During the mainten ance therapy period, Alise rtib will be administered by [CONTACT_1966], at 50 mg twice 
daily from day 1 to day 7 of a 21-day cyc le. All patients will receive up to 18 cycles, or unti l 
tumor progression. 
 
1.4 Preclinical Da ta 
1.4.1 In Vit ro Studies 
Alisertib is an adenosine triphosphate ( ATP)-competit ive and reversible inhib itor of Au rora A 
kinase in vi tro with an inhibition constant (K i) of 0.[ADDRESS_1007607]-116 human 
colorectal tumor cells, Alisertib produces 50% inh ibition of Au rora A kin ase activity a t a 
concentration of 6.7 nM. I t is approximately 200-fold more selective fo r Aurora A kinase than 
the structurally related family member, Au rora B kinase (half maximal inhibitory concentration 
[IC50] = 1534 nM). Moreover, in enzyme a ssays, Alisertib is selective for Aurora A kinase when 
compared to other kinases and receptors. Alise rtib has affinity for the gam ma acid alpha 1 
(GABAA α1) receptor benzodiazepi[INVESTIGATOR_050] (BZD) binding site (Ki = 290 nM). The consequences of 
GABAA binding in ra t and dog safety pha rmacology studie s are discussed be low. 
 
Consistent with the mechanism of action for an Aurora A kin ase inhibitor , Alisertib treatment 
results in formation of abnorma l mitotic spi[INVESTIGATOR_36874], an accumulation of mi totic cells, and a 
decrease in the proliferation of a bro ad range of tu mor cell lines grown in culture [49, 57, 58]. 
 
 
15 
Protocol #13P.528, v5.4 
(13September 2017) 
The in vitro antiproliferat ive effect of Alisertib was quanti fied in tumor cell lines derived f rom a 
variety of malignancies, including colon (3 cell lines), breast (1 cell line), lung (1), ovary (1 ), 
prostate (1), pancr eas (1), and lymphoi d (1). Alisertib inhibited proliferation with le thal 
concentrations for 50% cell-growth inhibitor concentrations (GI50 va lues) ranging from [ADDRESS_1007608] anti tumor activity in a dive rse array of experimental human  
tumor xenogra fts when dosed QD or BID. The se include 2 colon mode ls (HCT-116 and DLD-1), 
2 lung models (H460 and Calu-6), [ADDRESS_1007609] model (MDA-MB-231 FP4), 1 prostate  model 
(CWR22 RV-1 Luc1.17) and 4 DLBCL models (Ly19, WS U, Ly7, PHT X 22-06). Stati stically 
significant tumor growth inhibition (TGI ) was observed with Al isertib given at 30 mg/kg QD o r 
less in all models but the Cal u-6 model. At 20 mg/ kg BID or less, st atistically significant TGI 
was observe d in all models tested, including Calu-6. Taken toge ther, these results demonstra ted 
that Alisertib has broad antitumor activity in many expe rimental human tumor mod els. 
 
Alisertib also demonstra ted robust antitumor activity when combined with doce taxel in 
preclinica l models. Alisertib dosed daily at 3, 10 or 20 mg/kg QD wa s tested with doce taxel 
dosed weekly at 5 or 10 mg/kg in m ice bearing breast (MDA-MB-231 ), primary breast (PHTX- 
02), lung (H522) or prostate (CWR22 RV-1 Luc1.17) human tumor xenografts. The various 
combinations of the se agents at these doses were well tolerated, and resulted in synerg istic or 
additive antitumor activity re lative to the sing le agent activity of eithe r Alisertib or docetaxe l 
alone. In severa l of these models, the combination of Alise rtib and docetaxe l led to reg ression in 
tumor size and a dra matic prolongation in surviva l after termination of treatment. When the 
taxane was delivered in a regimen that overlapped Alisertib exposure during the f irst week of 
dosing, major enhanced anti tumor activity was obse rved when Alisertib was administered over a 
shorter (9-day) time period, and the magnitude of response and disea se control was comparable 
to results obtained with a longer (21-da y) dosing schedule. In the p rostate cancer mo del (CWR22 
RV1), the combination Alisertib (10 mg/kg QD) and doceta xel (10 mg/k g Q7D x 3) led to 
regression in tumor size and a dramatic prolongation in overa ll survival after termination of 
treatment. 
 
Clinical pharmacokinetic da ta available as of [ADDRESS_1007610]-dose. Neglig ible urinary excretion of Alise rtib was observed in 
humans. The re nal clearance of Alisertib in human s was less than 0.1% of apparent ora l 
clearance. Steady- state plasma exposures of Alisertib inc reased in an approxima tely dose- 
proportional manne r over the range of 5 to 200 mg/day in patients with advanced solid tumors. 
Overall mean steady-state terminal half-life following multiple-dose administration in patients 
with nonhema tologic malignancies was approximately 22 hours. The overal l mean peak/t rough 
ratios were 2.6 and 5.0 fo r BID and QD dosing, respectively. The overall mean accumulation 
ratios were 2.8 and 1.9 fo r BID and QD dosing, respectively. Pha rmacokinetic ste ady-state 
conditions we re approximately achieved by [CONTACT_2006] 7 following daily ora l administration. 
 
 
16 
Protocol #13P.528, v5.4 
(13September 2017) 
Based on the re sults of a population P K analysis in 294 adult cance r patients, the apparent oral 
clearance of MLN8237 CL /F was unaf fected by [CONTACT_654], body weight, BS A, or the UGT1A1 
genotype (number of *28 alle les). These results support the use  of a common fixed sta rting dose 
of MLN8237 independen t of UGT1A1 genotype status, age or b ody size in the adult patient 
population, in the ongoing and planned clinica l trials. 
 
Results from the re lative BA study in 14 patients indica ted that systemic exposure s achieved 
following administration of the enteric-coa ted-tablet (ECT) and powder- in-capsule (PI C) 
formulations of ML N8237 are generally similar, based on re lative BA of ECT in reference to  
PIC of approximately 90% (90% con fidence interval: 74.4%-108.8% ), supporting transition from 
the PIC to EC T in clinical development. 
 
The absolute bioavailability of Alisertib in humans has not been dete rmined; however, the 
single-dose pha rmacokinetic s of a prototype ora l solution for mulation of Alise rtib (25-mg dose) 
were characterized in reference to the PIC (50-mg dose ) in a cross-over relative bioavailabilit y 
evaluation in S tudy C14010 in 15 patients with nonhe matologic malignancies. Foll owing 
administration a s an oral solution, Alise rtib was rapi[INVESTIGATOR_24584], with a median T max of 1 hour. 
Based on preliminary PK data, the dose-no rmalized geome tric mean o f Alisertib Cmax and 
AUCinf achieved following administration of the ora l solution were approxima tely 78% and 
35% highe r, respectively, than those obse rved following PIC dosing. 
 
The effect of a stand ardized high-fa t meal on the PK of single dose Alisertib administered a s a 
50-mg strength EC T f ormulation was evaluated in [ADDRESS_1007611] formulation, unless other wise 
specified in the clinica l study protocol. 
 
1.5 Clinical Data to Date  
Clinical experience with Al isertib includes pha se 1 and 2 studies in both solid tumor s and heme- 
lymphatic malignancie s, described below. 
 
Alisertib for clinica l studies is being  developed in 3 dosa ge formulations:  p owder-in-capsule 
(PIC), enteric-coated- tablet (ECT), and ora l solution (OS : for pediatric use). The in itial studie s 
employed the PI C formulation, and more r ecent studies have eva luated safety, PK, relative 
bioavailability (in reference to the PIC ), and antitu mor activity after administration of the ECT 
formulation. 
 
Using the ECT formulation, the dose-es calation, phase [ADDRESS_1007612] formulation 
employed in this s tudy, multiple dose lev els up to 840 mg total cycle dose (60 mg BI D for 
7 days) were evaluated. At the maximum adminis tered dose of 60 mg BID for 7 days 
 
 
17 
Protocol #13P.528, v5.4 
(13September 2017) 
administere d to patients with advanced solid tumors, 3 patients (out of 3 enrolled) deve loped 
myelosuppre ssion during the tr eatment-free pe riod which was considered intolerable and above 
the MTD of 50 mg BI D. In summary, 700 mg total cycle dose (e.g., 50 m g BID administered 
daily for 7 days) represents the ceiling for dose esca lation in these combinations with Alise rtib 
planned for th is current study. 
 
The predominant tox icities reflect the mechanism of action in proliferati ng tissue (bone marrow, 
GI epi[INVESTIGATOR_2130], and ha ir follicles). The suggested management of these tox icities is based on 
standard clinical paradigms for an anti-prol iferative che motherapeutic agent. Using  a treatment- 
free period for re covery be tween each cycle of drug administration, the clinica l experience from 
multiple pha se 1 through 2 studies indi cate that major  toxicities can be ma naged to allow re peat 
treatment cycles ove r periods extending beyond 12 months. 
 
Alisertib is structurally re lated to the benzodiazepi[INVESTIGATOR_1651] (BZD ) (e.g., diazepam, lora zepam) and 
also has activity against the GABAAα1 BZD receptor. BZD-like eff ects (e.g., somnolence, 
confusion, memory loss) have been observed to be a ssociated with the onset of maximal plasma 
concentration (e.g., Tma x [time to maximu m plasma concentration] ). CNS effects associated 
with peak plasma l evels have been generally managed by [CONTACT_683606] (e.g., 
BID administration), although dose reductions have someti mes been required. While CNS 
effects attributed to Alise rtib were also generally reve rsible and manageable by [CONTACT_334320] o r 
reduction, the ca usal relationship, and thus optima l approach to management, we re sometimes 
conf
ounded by [CONTACT_737601], but not limited to, concomi tant medications (e.g., 
narcotic analge sics, antianxiety medications), comorbiditie s (e.g., infection, anemia, elec trolyte 
abnormalitie s), and progre ssive malignancy (e.g., bra in metastases). 
 
1.6 Dose Ra tionale and Ris k/Benefits 
The safety risks of Alisertib tr eatment a re: (1) leukopenia, neutropenia, fe brile neutropenia, and 
lymphopenia with a potentia l inc reased sus ceptibility to inf ection; (2) thrombocytopenia with a 
potential inc reased risk o f bleeding; (3) anemia ; (4) gastrointestinal (GI) toxicity resulting in 
stomatitis/mucositis, naus ea, vomiting, anorex ia, abdominal pain, dyspepsia, diarrhea, 
dehydration, and potentially mucosal/GI bleeding, and sepsis ; (5) alopec ia; (6) asthenia/fatigue; 
(7) fever; and (8) benzodiazepi[INVESTIGATOR_050]-like eff ects including sedation, somnolence, sleep disorde rs, 
confusion, disor ientation and a ssociated memory loss and ga it disturbances (which we re 
reversible in clinical studies with cessation of treatment or dose re duction).  Skin ch anges 
including hand-foot synd rome have been reported in some patients. Clinica l safety data includes 
experience from pa tients who re ceived mult iple cycles followed by [CONTACT_3148]-free periods 
between each cycle, and from patients who re duced or discontinued tr eatment. Based on the 
available clinical data, drug abuse, dependency, and withdrawa l were not observed. 
 
While these toxicit ies are potential ly associated with risk or discomfor t to the patient, they ar e 
anticipated to be reve rsible. Alisertib has not led to major neurotox icities or fluid retention as a 
single agent. Howeve r, because there is only limited human expe rience with Al isertib, it is 
possible that Alis ertib will have  other toxicities that have not been obser ved in, or pre dicted 
based on, ra t, dog, and human studie s. Alisertib has a low potential to prolong the QT interval in 
vivo based upon it s extremely weak in vitro binding to hER G (IC50 and Ki both > 100 µM). 
 
 
18 
Protocol #13P.528, v5.4 
(13September 2017) 
To mitiga te the inherent risks in clin ical studies of Alise rtib, patients are eva luated frequently 
while they are receiving treatment. 
 
Because Alisertib inhibits Aurora A kinase, it is possi ble that Alisertib may in terfere wi th cancer 
growth and cause cancer cell death through a potentially non-c ross resistant pathway as 
compared to other agents that patients ma y have received. The clinica l utility of these effects will 
be investigated in current and future  studies. 
 
2.0 Study Objec tive 
2.1 Primary Objec tives: 
1.   Evaluate the safety and tole rability of the study treatment 
2.   To de termine the M aximum Tolera ted Dose (MTD) of daily oral ALISERTIB when 
combined with fractiona ted stereotactic radiation treatment for re current high gra de 
glioma. 
 
2.2 Secondary Objec tives: 
1.   To estimate [ADDRESS_1007613] of quality of life (QoL) 
 
3.0 STUDY DESIGN  
3.1 General Design  
 
 
3.2 Primary S tudy Endpoin ts 
1.   Evaluate the safety and tole rability of the study treatment 
2.   To de termine the M aximum Tolera ted Dose (MTD) of daily oral ALISERTIB when 
 
 
19 
Protocol #13P.528, v5.4 
(13September 2017) 
combined with fractiona ted stereotactic radiation treatment for re current high grade 
glioma. 
 
3.[ADDRESS_1007614] of quality of life (QoL) 
 
3.4 Primary Safe ty Endpoints 
To determine the M aximum Tolera ted Dose (MTD) of daily oral ALISERTIB when combined 
with fractionated stereotactic ra diation treatment for recur rent high gra de glioma. 
 
4.[ADDRESS_1007615] a previously histolog ically or cytolog ically confi rmed high grade 
glioma (astro cytic or oligodendroglial supra tentorial tumors grade 3 or 4 ) that has been 
previously tr eated with fractiona ted radiation the rapy and no w shows evidence of 
recurrence. 
2.   Patients must have recovered from the to xic effects of prior therapy. 
3.   Patients must have recovered from the effec ts of surgery. There must be a minimum of [ADDRESS_1007616] a 2-week break between prior tr eatment and the protocol treatment. 
5.   Prior treatment with fractionated radiation therapy (up to 60Gy) is an eligibility criterion, 
however there should not have been a second cour se of fractionated radiotherapy to t he 
supratentorial area. 
6.   One prior si ngl e fraction radiosurg ical procedure with in the treatment field is acceptable 
if V12<5 cc (V12 is the volume of n ormal brain (outside GT V) receiving 12 or more Gy ). 
Additiona l radiosurgical procedures outside of the treatment area a re acceptable. 
7.   Subjec t must be able to take ora l medication and t o maintain a  fast, is required for 2 hou rs 
before and 1 hour a fter MLN8237 administration. 
8.   ANC > 1500/mm³, pla telets > 100,000/mm³, Hgb > 9 g/dL. Values must be obtained 
without need for mye loid growth factor or pla telet transfusion support within 14 day s of 
registration. Howe ver, erythrocyte g rowth factor is allowed as per published AS CO 
guidelines. 
9.   Total bilirubin ≤ UL N, SGOT (AST) and SGPT (ALT)< 1.5 x UL N, within 14 day s of 
registration. 
10. Adequa te renal function as defined by : [CONTACT_737602] c learance must be ≥40 
mL/minute ( Cockcrof t-Gault), within 14 day s of registration. 
11. Age >18 yea rs. 
12. ECOG perfo rmance status <2 (see Appendix I). 
13. Life expectan cy of greater than [ADDRESS_1007617] 
documente d within 7 days prior to reg istration. 
 
 
20 
Protocol #13P.528, v5.4 
(13September 2017) 
15. Women of child-beari ng potential and men must agree to use adequate contra ception 
(hormonal or barr ier method of birth control; abstinence) prior to study entry and for [ADDRESS_1007618] dose 
of study drug, o r other severe infection. 
3.   Myoca rdial infarction wi thin 6 months prior to en rollment, Ne w York Hea rt Association 
(NYHA) Class III or IV heart failure, uncontrolled angina , severe uncontrolled 
ventricular arrhythmias, or electrocardiographic evidence of acute is chemia or active 
conduction sy st em abnormalities. Prior to study entry, any ECG abnormal ity at Screening 
has to be documented by [CONTACT_737603]. 
4.   Female subject is pregnant or breast-f eeding. Confirmation that the subject is not 
pregnant must be established by a negative serum -human chorionic gonadotropin ( -
hCG) pregnancy test result obtaine d during screening . Pregnancy testing is not required 
for post-menopausa l or surgically ste rilized women. 
5.   Patient has re ceived other investigational drugs within [ADDRESS_1007619]. John's wort within [ADDRESS_1007620] dose of MLN8237 and 
during the study. 
9.   Known history o f human immunodef iciency virus (HIV) infection, hepatiti s B, or 
hepatitis C.  Testing is not required in the absence of clinical finding s or suspi[INVESTIGATOR_2798]. 
10. Patients have a history of any othe r malignancy from which the patient has been disease- 
free for less than 2  years, with the exception of adequa tely treated basal or squamous cell 
carcinoma of skin, superf icial bladder cancer or carcinoma in situ of cervi x, AJCC 
(version 7.0) st age [ADDRESS_1007621] cancer, AJCC (version 7.0) stage  I, or II prostate cancer. 
11. Radiation therapy to more than 25% of the bone ma rrow. W hole pelvic radiation is 
considered to be ove r 25%. 
12. Patients who cannot swallow whole tabl ets (i.e. medication table ts) 
 
4.3 Gender/Minority/Pediatric Inclusion for Research  
This study includes both gende rs and minority patients. Pe diatric patients a re excluded. 
 
 
21 
Protocol #13P.528, v5.4 
(13September 2017) 
 
4.4 Subjec t Recruitmen t and Screening 
Patients who a re 18 years of age or olde r with high grade gli omas are eligible for the stu dy. 
Patients can be r ecruited from PI o r co-investigators’ clinica l practices. Principal Investigator 
[INVESTIGATOR_737572]/research associates should be noti fied of potential study  subjects. 
Appropriate laboratory or diagnostic te sting necessary to m eet any noted inclusion or exclusion 
criteria will be ordered through the rec ruiting physician. PI [INVESTIGATOR_737573] /research associate will screen and de termine the final eligibility of the subjec t for 
enrollment. 
 
4.[ADDRESS_1007622] the right to withdra w from the stu dy at any ti me for any 
reason, without prejudic e to their medical care. The investigato r also has the right to withdra w 
patients from the stu dy for any of the foll owing reasons: 
1.   Intercurrent illne ss 
2.   Occurrence of an unacceptable adverse event 
3.   A treatment delay > [ADDRESS_1007623] iance 
7.   Admini strative reasons 
8.   Failure to return for follo w-up 
9.   Genera l or specific changes in the patie nt’s condition that make it unaccep table to 
continue tr eatment, in the judgment of the inve stigator 
10. Progressive disea se 
 
At the time of withdrawa l, all study procedures outlined for the End of Study visit should be 
completed. The prim ary reason for a patie nt’s withdra wal from the stu dy is to be reco rded in the 
source documents. 
 
4.5.[ADDRESS_1007624] who discontinues stu dy treatment needs to sta te whether he/she wishes to continue 
participating in the study and all ow further data collection as par t of long term follow-up. 
Subjects who choose to continue with the study will participate in follow-up visits and 
evaluations according to the protocol. Subjec ts who refuse to participate in follow-up will be 
withdrawn from the stu dy. 
 
Study data collected prior to a subject’s withdr awal from the stu dy will be included in the stu dy 
analysis. 
 
 
22 
Protocol #13P.528, v5.4 
(13September 2017) 
5.[ADDRESS_1007625] dos age form in 10 mg strength, with dose s trength expressed as 
the milligra ms of active drug (free acid). 
 
5.[ADDRESS_1007626] Common (≥ 30%)  
• Nausea, diarrhea  
• Decreased numbe r of white blood cells, which may incr ease risk of infecti on 
• Damaged mucous membranes in the mouth (mouth blisters)  
• Decreased numbe r of red blood cell s (or anem ia) which may cause feelings of tiredne ss 
• Weakness or feeling tired 
• Hair loss 
 
Very Common (10% and <30%)  
• Pain, including muscle pain, chest pain, and pain from can cer 
• Fever with or without decreased white blood cells 
• Sleepi[INVESTIGATOR_737574] 
• Bleeding events with or without decreased numbe r of blood pla telets 
• Cough  
• Shortne ss of breath 
• Rash/skin eruption  
• Constipation 
• Vomiting 
• Decrease in weight or loss of appeti te 
• Fluid retention and swelling (e.g ., hands, f eet, legs) 
• Headache 
• Dehydra tion (decr eased body f luids) 
• Dizziness 
 
Common (>1% and <10%)  
• Confusion and menta l status changes 
• Imbalance whi ch can lead to falling  
• Anxiety or depression 
• Difficulty sleepi[INVESTIGATOR_007] 
 
 
23 
Protocol #13P.528, v5.4 
(13September 2017) 
• High or low blood pre ssure 
• Itchy or dry skin 
• Bruises 
• Inflamed or dry eyes, blur red vision 
• Dry mouth  
• Difficulty or painful when swall owing, altered taste 
• Upset stomach, fla tulence 
• Difficult or blo cked bowe l movements 
• Hemorrhoids  
• Runny nose, sinus or voice pro blems 
• Numbne ss or tingling in hands or feet  
• Abnor mal heart rhythm 
• Ringing in the ea rs 
• Muscle spasms/w eakness 
• Fluid around the lu ngs or abdomen  
• Increased sweating or chills 
• Abnor mal kidney function  
• Abnor mal liver function test 
• Abnor mal levels of blood suga r, chemistry, protein or blood clotting ti me 
• Bacterial, fungal or viral inf ection 
• Increased blood bilirubin  
• Blood clot (usually in the le gs) 
• 
Loss of bladder control  
 
Uncommon (< 1%)  
Serious and tr eatment-rela ted adverse events include: rhabdomyoly sis (muscle breakdown that 
can dama ge kidneys), bone fracture, blistering skin reaction, multi ple organ failure , deafness, 
shock, hepatic veno-occlusive disea se (also known as sinusoidal obst ruction syndrome), hea rt 
problems, agitation or ir ritability, and injury to one or mo re organs tha t may be life-threatening 
or fatal. 
 
5.4 Method  of Assigning Subjec ts to Treatment Groups 
This is an open label phase I study. 
 
5.5 Preparation and Ad ministration of S tudy Drug 
Alisertib will be adminis tered on an e mpty stomach with the patient re maining NPO (nothing by 
[CONTACT_1966]), ex cept  for water and prescribed medications, for [ADDRESS_1007627] ructed to take  each oral dose of Alisertib with 8 ounc es (1 cup, 240 
mL) of water. 
 
Alisertib will be supplied as [ADDRESS_1007628], with the do se strength expre ssed as milligrams of 
active drug (free acid). A ll tablets are to be inge sted whole; patients who have diff iculty 
swallowing tablets will be excluded f rom the stu dy. 
 
 
24 
Protocol #13P.528, v5.4 
(13September 2017) 
5.[ADDRESS_1007629] will be reviewed and reco rded. 
 
5.7 Prior and Conco mitant Therapy 
Anti-emetogenic agents may be administered a t the discretion of the investigator. Although not 
prohibited, the use of benzodiazepi[INVESTIGATOR_737575] p rophylaxis or treatment of na usea or vomiting is 
discouraged b ecause of the potential b enzodiaze pi[INVESTIGATOR_050]-like effects of Alisertib. 
 
Other medications, such a s PPIs, H2 antagonists, growth factors, glucocorticoids, anti-e metics, 
and anti-epi[INVESTIGATOR_23935] s are permitted at the treating phys ician’s discretion. 
 
All patients will r eceive concurrent FSRT to the r ecurrent gli oma. 
 
5.[ADDRESS_1007630], with the dose strength expre ssed as milligrams of 
active drug (free ac id). 
 
5.[ADDRESS_1007631] be perfo rmed and a dru g receipt 
log filled out and signed by [CONTACT_17247]. I t is important tha t the designated 
study staff counts and ve rifies that the shipment contains a ll the items noted in the shipment 
inventory. Any damaged or unusa ble study drug in a given shipment (active drug  or comparator) 
will be documented in the stu dy files. The investigator must notify study sponsor of any 
damaged or unusa ble  study treatments tha t were supplied to the investigator’ s site. 
 
5.10.[ADDRESS_1007632] en sure that it is stored in accordance with the environmental conditions a s 
determined by [CONTACT_737604] C/reference la bel. 
Alisertib must be stored at room tempe rature. 
 
5.10.[ADDRESS_1007633] of Alisertib disposition is 
maintained at ea ch study si te where Alisertib is inventoried and disposed o f. Records or logs 
 
 
25 
Protocol #13P.528, v5.4 
(13September 2017) 
must comply with applica ble regulations and guideline s and should include: 
• Amount r eceived and placed in storage a rea. 
• Amount currently in stora ge area. 
• Label ID numbe r or batch number and use da te or expi[INVESTIGATOR_737576]. 
• Non-study disposition (e.g., lost, wasted, b roken). 
 
At the completion of the study, there will be a f inal reconciliation of drug shipped, dru g 
consumed, and dru g remaining. This reconcil iation will be logged on the d rug reconciliation 
form, signed and da ted. Any discrepanc ies noted will be investiga ted, resolved, and documented 
prior to return or de struction of unused study drug. Drug de stroyed on site will be documented in 
the study files. 
 
6.0 STUDY PROCEDURES 
6.1 Study Visit Sche dule 
Please see Appendix II for stu dy calendar. 
 
6.2 Defin ition of  Dose-Limiting Toxicities  
Dose-limiting toxicities (DLTs) will be graded in seve rity according to the guidelines outlined in 
the NCI- CTCAE v ersion 4.0. Dose-limiting hema tologic and non-he matologic toxicities will be 
defined differently, and will be based on events that occur du ring study drug administration and 
for [ADDRESS_1007634] be re lated (definitely, probably, or po ssibly) to study 
therapy. 
 
If a patient expe riences a DLT during the radiation pha se or the 30 day pos t radiation observation 
period, the patie nt will be permanently discontinued from study. 
 
A dose-limiting toxicity (DLT) will be defined as follows: 
• All grade 3 or highe r toxicities that occur during o r within 30 day s of completing 
radiation treatme nt will be considered “ treatment re lated” with the exception of (1) 
symptoms that are clearly related to the cance r or other pathology (in the opi[INVESTIGATOR_737577]), and (2) expected s equelae of the neurosurgi cal procedure or 
radiosurgery. All neurological symptoms will be considered “tr eatment rela ted” unless 
they are present at study onset, expected s equelae o f the neurosurgi cal procedure, or 
clearly related to disease progression. 
• Febrile neutropenia (even in the a bsence of  hospi[INVESTIGATOR_059]) 
• Hematologi c DLTs will be de fined as either Grade 4 neutrope nia lasting for ≥ 7 days in 
duration, any Grade 4 anemia, any Grade 4 thrombocy topenia, or any G rade 5 
hematologic toxicity. All patients will be eva luated for hematologic toxicity. 
• Any neurolog ical toxicity of Grade 3, 4 or 5 will be considered a DL T, with the exception 
of 1) symptoms present p rior to study en rollment, and 2) expected s equelae of the 
neurosurg ical procedure. 
• Grade 3 event of hypo calcemia, hypophospha temia, hypoka lemia, or hypomagnesemia 
lasting more than 24 hou rs without responding to medical therapy; or responding to 
medical therapy and lasting mo re than 72 hours 
• Grade 3 transaminases elevation associated with ≥ grade 2 bilirubin e levation (Hy ’s law) 
 
 
26 
Protocol #13P.528, v5.4 
(13September 2017) 
will also be a DL T defining event. 
• Non-hematologic dose-limiting toxicity will be de fined as any Grade 3, 4 o r 5 non- 
hematologic toxicity, with the specific  exception of: 
o Grade 3 nausea or Grade 3 vomiti ng that in the opi[INVESTIGATOR_737578] 48 hour s. 
o Grade 3 diarrhea that in the opi[INVESTIGATOR_737579] 48 
hours. 
o Grade 3 dehydra tion that, in the opi[INVESTIGATOR_737579] 48 
hours. 
o Grade 3 acidosis or alkalosis whi ch responds to medi cal intervention by [CONTACT_737605] ≤ Grade 2 within 48 hours. 
o Isolated G rade 3 elevation of live r function tests (LF Ts) without a ssociated 
clinical symptoms, lasting  for ≤ 14 days in dura tion. 
o Grade 3 hypo calcemia, hypokalemia, hypomagnesemia, hypona tremia, or 
hyphosphatemia whi ch responds to medi cal intervention. 
o Grade 3 hyperchole sterolemia. 
o Grade 3 hype rtriglyceridemia. 
o Grade 3 alopec ia 
 
6.3 Dose escalation/de-escalation  
Dose escalation wil l proceed within each cohort according to a “3+3 design”, a s explained in the 
following scheme. Dose-limiting toxicity (DL T) is defined above. The to xicity assessment 
period is 30 day s after the completion of the radiation the rapy. 
 
Dose Level Alisertib dose 
-1 10 mg BID 
1 20 mg BID 
2 30 mg BID 
3 40 mg BID 
4 50 mg BID (final dose level) 
 
Number of Patients with 
DLT at a Given Dose 
Level†  
Escalation D ecision Rule 
0 out of 3  Enter 3 patients at the next dose level. 
>2 Dose escalation will be stopp ed. This dose  level will be 
declared the m aximally administered dose (highest dose 
administered) . Three (3) additional patie nts will be entered a t 
the next lowest dose lev el if only [ADDRESS_1007635] 3 more patients at this dose  level. 
•   If 0 of these 3 patients expe rience DLT, proceed to the nex t 
dose level. 
 
 
27 
Protocol #13P.528, v5.4 (13September 2017)  
 
  
 
 •   If 1 or more of this group  suffer DLT, then dose escalation is 
stopped, and thi s dose is d eclared the maximally 
administered dose . Three (3) additional patients wil l be 
entered at the next lowest dose level if only 3 patients were 
treated previously at that dose. 
<[ADDRESS_1007636] be ente red at the recommended phase 2 dose. 
†Dose escalation will be determined based on the occurrence of DLTs. For the purposes of 
determining whether to  advance the Dose Level, DLTs will be counted by [CONTACT_128666] (i.e., a 
patient who experiences more than 1 DLT will be counted on ly once). 
 
6.[ADDRESS_1007637] radiation obse rvation 
period the patie nt will be permanently discontinued from the stu dy. 
 
Maintenance treatment wit h Alisertib will be repeated every 21 day s. In order for a new cyc le of 
therapy to begin, t he patient’s ANC must be ≥ 1,500/mm3 and the plat elet count must be ≥ 
75,000/mm3. In addition, any othe r toxicity considered by [CONTACT_737606] ≤ Grade 1 or to the patient ’s baseline va lue before a 
new cycle of th erapy may begin. 
 
If the patient fails to m eet the above-cited c riteria for retreatment, then initiation of the n ext cycle 
of therapy will be delayed for up to [ADDRESS_1007638] b een met. Should treatment need 
to be delayed for mo re than 1 w eek (i.e., a rest period of more than 21 days ) because of 
incomplete  recovery fro m treatment-rela ted toxicity, the dose of Alise rtib will be re duced 1 leve l 
when therapy resumes. A second dose reduction may o ccur should tr eatment need to be delayed 
for more than 1 week because of incomplete recovery f rom treatment-re lated toxicity on the 
reduced dosage. Should treatment need to be delayed for more than 2 weeks at any dose, therap y 
with
 Alisertib will be discontinued (T able 1). 
 
Table [ADDRESS_1007639] maintenance dose of 50 mg BID. 
 
Dose Modifications for He matological Toxicity 
If a patient expe riences any of the following  hematological toxicities during the dosing period, 
dosing will be discontinued for the remainder of that cycle and the dose wi ll be decre ased 1 leve l 
for all subsequent cyc les of treatment. 
1.    
2.   Grade 4 thrombocy topenia (platelet count < 25,000/µL ) lasting more than 7 consecutive 
 

 
28 
Protocol #13P.528, v5.4 (13September 2017) days 
3.   Grade 3 neutropenia with fever or infection, or both, whe re fever is defined as an oral 
temperature greater than 38.5°C 
4.   Grade 3 thrombocy topenia with clinically sig nificant bleeding 
 
If a patient ha s a platelet count of le ss than 10,000/µ l at any time, the pat ient will be removed 
from the stu dy permanently. 
 
Hematopoietic  growth factors are allowed for fe brile neutropenia or prolonged neutropenia, o r 
decided app ropriate by [CONTACT_74079]. The choice of growth fac tor, dose, and dura tion is 
up to the tr eating physician. CBC should be monitored no less than [ADDRESS_1007640] 
resolved to ≤ G rade 1 or to baseline. 
1.   Any Grade 2 or gr eater neurologi cal toxicity 
2.   Any Grade 3 non-he matological toxicity that is considered by [CONTACT_227044]: 
3.   Grade 3 arthralgias/ myalgias 
4.   Grade 3 or greater nausea or emesis, or both, that occurs in the absence of opti mal 
antiemetic therapy (5-hydroxytryptamine 3 [5 -HT3] serotonin receptor antagonist) 
5.   Grade 3 or greater diarrhea that o ccurs in the absence of o ptimal supportive therapy with 
loperamide 
6.   Grade 3 fatigue that lasts  gr eater than 1 week  
7.   Grade 2 non-he matologica l toxicities that are considered by [CONTACT_737607][INVESTIGATOR_737580]. 
 
In general, Alisertib treatment should be discontinue d if a patient expe riences a nonhematologic 
grade 4 tox icity. If, in the opi[INVESTIGATOR_737581]’s 
interest to continue therapy with Alisertib, then after recovery from the to xicity or toxicities in 
question to ≤ grade [ADDRESS_1007641] 1 
dose level with subsequent cycles of therapy. 
 
When a dose re duction of Alise rtib is required, no re-es calation of dose will  be permitted. If a 
patient require s more than 2 dose re ductions, therapy with Alisertib will be dis continued. 
 
6.5 Quality of Life Measurement  
The validated EORTC core quality o f life questionnaire (QLQ-C30, ve rsion 3.0) supple mented 
by a brain cance r specific health-related quality of li fe questionnaire, QLQ-BN20, wil l be 
administered according t o trial calendar. (Appendix V) 
 
6.6 Define Prog ression 
The progression of the gli oma will be defined according to Updated Response Assessment  
 
 
29 
Protocol #13P.528, v5.4 (13September 2017) Criteria for High-G rade Gliomas: Response A ssessment in N euro-Oncology Work Group  
(RANO criteria) [59, 60]. 
 
7.0 STATISTICAL PLAN 
7.1 Samp le Size Determination  
We use 3+3 design for th is trial. We estimate up to 24 patients.  
 
7.2 Statistical Methods 
We will use a two-stage accrual design at each dose considered. We will in itially enter 3 subjects 
at each dose. I f none of the three expe riences a dose-limiting toxicity we will proceed to the nex t 
dose.  If one o f the three expe riences that leve l of toxicity, we will a ccrue 3 more subjects at that 
dose. If at any time there are two or mo re dose-limiting toxicities (in the 3-6 subj ects) on a given 
dose, we will terminate accrual to the Phase I portion of tha t trial. No pat ient will be treated at a 
higher dose until the [ADDRESS_1007642] completed their to xicity evaluation period at the cur rent 
dose. With this plan, a do se with a 50% or gr eater probability of causing a dose-limiting toxicity 
has at most a 12.5% chance of s atisfying the conditions for dose esca lation after the first [ADDRESS_1007643] a 50% chance of stoppi[INVESTIGATOR_25577] 3. With the two- stages (3-6) togeth er, there is at 
most a 17.2% chance of satisfying the conditions for dose esca lation after the 6 subjects. 
 
The maximally tolerated dose (MT D) will then be the last dose studied or the previous dose, 
based on Inve stigator’s clinical judgment of the degree of toxicity seen at the last dose. Whil e 
waiting fo r the 3 or 6 sub jects accrued according to plan to comple te their toxicity evaluation 
period, up to 3 additiona l subjects may be accrued at the current dose . These additional subj ects 
will not count towards the formal plan of stoppi[INVESTIGATOR_007] a t two or more  toxicity occurrence s, but will 
contribute to the judgment as to the MTD.  
 
We will also conduc t some descriptive analyses that will help in the design of a possible phase- II 
trial. Among patients a t the MTD in each arm, we will estimate the proportion with comple te or 
partial response, as well as the medi an surviva l (through the Kaplan- Meier method). We will also 
compute a ssociated 95% confidence in tervals, although we real ize that they will be very wide 
(given tha t we only anticipa te 6-8 patients to be trea ted at the MTD in each arm). The estimates 
themselves, howe ver, will help in the sample si ze calculations of possible future phase- II trials. 
 
Progression free survival and overa ll survival will be measured from the da te of starting study 
treatment (f irst day of radiation treatment). Progre ssion free survival will be assessed by [CONTACT_737608]. 
 
7.3 Subjec t Populatio n(s) for Analysis 
All subjects who rece ived the radiation treatment per the p rotocol and concurre nt Alisertib will 
be subjected to the stu dy analysis – both fo r the primary analy sis and any appli cable secondar y 
analyses. 
 
8.0 SAFETY AND ADVERSE EVENTS  
8.1 Defin itions 
Adverse Event 
An adverse event (AE) is any symptom, sign, illne ss or experience that d evelops or worsens in 
 
 
30 
Protocol #13P.528, v5.4 (13September 2017) severity during the course of the stu dy. Intercur rent illnesses or injuries should be rega rded as 
adverse events.  Abnorma l results of diagnostic procedures a re considered to be adverse events i f 
the abnormality: 
• results in s tudy withdrawal 
• is associated with a se rious adverse event 
• is associated with clin ical signs or sy mptoms 
• leads to addit ional treatment or to fur ther diagnostic te sts 
• is conside red by [CONTACT_737609] l significance 
 
Serious Adve rse Event 
Adverse events are c lassified as serious or non-serious. 
 
A serious adverse event is any AE that is: 
• fatal 
• life-thr eatening 
• require s or prolongs a hospi[INVESTIGATOR_4408] 
• results in pe rsistent or signi ficant disability or in capacity 
• a congenita l anomaly or birth defect  
• an important medica l event 
 
Important medica l events are those tha t may not be im mediately life threatening, but a re clearly 
of major clinical significance. They may jeopardize the subject, and may require in tervention to 
prevent one o f the other serious outcomes noted above. For exa mple, drug overdose or abuse, a 
seizure that did not re sult in in-patient hospi[INVESTIGATOR_11298], or intensive tr eatment of bronchospa sm in 
an emergency depa rtment would typi[INVESTIGATOR_15355]. 
 
All adverse events tha t do not meet any of the c riteria for serious should be regarded as non- 
serious adverse events. 
 
Adverse Event Reporting Pe riod 
The study period durin g which adverse events must be re ported is nor mally defined as the period 
from the in itiation of any study procedures to t he end of the stu dy treatment follo w-up.  For th is 
study, the study treatment follow-up is de fined as [ADDRESS_1007644] day of treatment 
(radiation treatment and/or Alise rtib). 
 
Preexisting Condition 
A preexisting condition is one that is pr esent at the sta rt of the stu dy. A preexisting condition 
should be reco rded as an adve rse event if the frequency, intensity, o r the character of the 
condition worsens during the study period. 
 
General Phy sical Examination Findings 
At screening, any clinica lly significant abno rmality should be r ecorded as a preex isting 
condition.  At the end of the study, any ne w clinically sig nificant findings or abnormalitie s that 
meet the definition of an adve rse event must also be recorded and documented a s adverse events. 
 
 
31 
Protocol #13P.528, v5.4 (13September 2017) Post-study Adverse Event 
All unresolved adve rse events should be followed by [CONTACT_737610], the subj ect is lost to follow-up, or the adverse event is otherw ise explained. At the la st 
scheduled visit, the investigator should i nstruct each subj ect to report any subseque nt event(s) 
that the subject, or the subjec t’s personal physician, believe s might reasonably be re lated to 
participation in this s tudy. The investig ator should not ify the study sponsor of any death o r 
adverse event occur ring at any time after a subject has discontinued or te rminated study 
participation that may reasonably be re lated to this s tudy. The sponsor should also be noti fied if 
the investigator should b ecome aware of the development of cance r or of a congenital anomal y 
in a subsequently conceived of fspring of a subj ect that has participated in this s tudy. 
 
Abnormal Laboratory Values 
A clinical laboratory abnor mality should be docu mented as an adverse event if any one of 
the following  conditions i s met: 
• The laboratory abnormal ity is not otherw ise refuted by a repea t test to confirm the 
abnormality 
• The abnormality suggest s a disease  and/or organ tox icity 
• The abnormality is of a  degree that requires active management; e.g. change of dose, 
discontinuati on of the drug, more frequent follow-up assessments, fu rther diagnostic 
investigation, e tc. 
 
Hospi[INVESTIGATOR_059], Prolonged Hospi[INVESTIGATOR_737582] t results in hospi[INVESTIGATOR_737583] a s a serious adve rse event unle ss specifically instructed other wise in 
this protocol. Any condition responsi ble for surgery should be documented a s an adverse event if 
the condition m eets the criteria for an adve rse event. 
 
Neither the condition, hospi[INVESTIGATOR_11298], prolonged hospi[INVESTIGATOR_059], nor surgery a re reported a s an 
adverse event in the follo wing circumstance s: 
• Hospi[INVESTIGATOR_737584] d iagnostic o r elective su rgical procedure s 
for a preexisting condition. Surgery should not be reported a s an outcome o f an adverse 
event if the purpose of the surgery was elective or diagnostic and the outco me was 
uneventful. 
• Hospi[INVESTIGATOR_737585]. 
• Hospi[INVESTIGATOR_737584] t herapy of the target disease of the stu dy, 
unless it is a worsening o r increase in frequency of hospi[INVESTIGATOR_737586] e 
clinical investigator. 
 
8.[ADDRESS_1007645] se ek information on adve rse events by 
[CONTACT_5147], a s appropriate, by [CONTACT_5148]. In formation on al l adverse events 
should be reco rded immediately in the source doc ument, and also in the appropria te adverse 
event module of the case report for m (CRF). All clearly related signs, sy mptoms, and abnorma l 
diagnostic pro cedure results should be grouped under one diagnosis and recorded in the sourc e 
document. 
 
 
32 
Protocol #13P.528, v5.4 (13September 2017)  
All adverse events occurring during the study period must be recorde d (see Appendix III). 
 
The clinical course of each event should be followed unti l resolution, stabil ization, or unti l it has 
been dete rmined that the study treatment or pa rticipation is not the cause. Serious adverse events 
that are still ongoing a t the end of the stu dy period must be followed up to dete rmine the final 
outcome. Any serious adve rse event that occu rs after the study period and i s considered to be 
possibly re lated to the st udy treatment or study participation should be recorded and repo rted 
immediately. 
 
8.[ADDRESS_1007646] dose. 
 
8.5 Data and Safe ty Monitoring Plan  
It is the responsibility of the P rincipal Investigator to oversee the safety of the study at his/her 
site.  This safety moni toring will include ca reful assessment and appropria te reporting of advers e 
events as noted above, as we ll as the compliance and im plementation of the KCC  data and 
safety-moni toring plan (DSMP). Medical monitoring will include a re gular assessment of  the 
number and type of serious adverse events by [CONTACT_36552] a ssigned Medical Monitor and the K CC 
DSMC. 
 
8.5.1 Med ical Monitoring and AE /SAE Repor ting 
A Medical Monitor i s assigned to this s tudy at the Thoma s Jefferson Univer sity. This is a 
physician or pharmacist who is not dir ectly involved in the trial, and is not currentl y 
collaborating with the sponsor/investigator on any other trial. The  role of the Medical Monitor i s 
to review all reportable AEs and SAEs (in real-ti me) including g rading, toxicity assignments, 
non-reportable AEs (qu arterly), protocol violations/deviations, a s well as all other safety data and 
activity da ta observed in the ongoing clinica l trial occurrin g at Thoma s Jefferson Univer sity. The 
Medical Monitor may recommend reporting of adve rse events and re levant safety data, and may 
also recommend suspension or te rmination of the study to the DSMC and TJU IRB. 
 
Every KCC investigato r initiated protocol include s requirements for reporting of adverse events 
based on CTC 4.0. All events are reported to the IRB and Medical Monitor using a pa ssword 
protected web-site. In addition all unexpected and serious adverse events (S AEs) are reported to 
the TJU IRB and to the Food and Drug Administration (FDA ) if applicable. The investig ator is 
required to submi t all unexpected and serious adve rse events to the TJU IRB and the Medica l 
Monitor within the ti meframes outlined in the bel ow table. All AE/SAEs will be reported to t he 
DSMC at the quarterly DSMC review meetings; however, if the Me dical Monitor de termines 
corrective action is necessary, an “ad hoc” DSMC me eting will be called. Fatal adverse  events 
related to t reatment which are unexp ected mus t be re ported w ithin 24 hour s to the TJU 
IRB and the DSM C. Fatalities not related to the study drug/de vice must be reported w ithin 
5 days. A summ ar y of the reporting require ments for KCC investigator init iated Phase I and 
 
 
33 
Protocol #13P.528, v5.4 (13September 2017) Phase II studies are presented be low. 
 
 Grade [ADDRESS_1007647] 
ed with 
Hospi[INVESTIGATOR_737587] 
d 
Unlikely Reviewed 
at 
Quarterly DSMC 
Meeting 
and IRB Annual 
Review Reviewed 
at 
Quarterly DSMC 
Meeting 
and IRB Annual 
Review Reviewe 
d at 
Quarterl y 
DSMC 
Meeting 
and IRB 
Annual 
Review 5 
Working 
Days Reviewed at 
Quarterly DSMC 
Meeting and 
IRB Annual 
Review 5 Working 
Days Reviewed at 
Quarterly DSMC 
Meeting and 
IRB Annual 
Review Phase 1 - 
48 Hours 
(Death: 24 
Hours) 
 
Phase 2 - 
5 Working 
Days 
Possible 
Probable 
Definite Reviewed 
at 
Quarterly 
DSMC 
Meeting 
and IRB Annual 
Review 5 
working 
days Reviewe 
d at 
Quarterl 
y 
DSMC 
Meeting 
and IRB 
Annual 
Review 48 Hours 
(Death: 
24 
Hours) Phase 1 - 
48 Hours 
 
Phase 2 - 
5 Working 
Days 48 Hours 
(Death: 24 
Hours) Reviewed at 
Quarterly 
DSMC 
Meeting and 
IRB Annual 
Review Phase 1 and 
Phase 2 - 
48 Hours 
(Death: 24 
Hours) 
**NOTE: This table is based on the NCI AE /SAE reporting Guidelines and the TJU IRB Po licy and Procedures. 
Please follow the individu al protocol A E/SAE reporting guidelines if more stringent reporting procedures are 
specified. 
 
In accordance with [ADDRESS_1007648] comply with following  safety reporting requirements: 
 
Expedited IND Safe ty Reports: 
7 Calendar-Day Telephone or F ax Report: 
The Sponsor-Inve stigator is required to notify the F DA of any fatal or life-threateni ng adverse 
event that is unexpected  and assessed by [CONTACT_737611]. An unexpected  adverse event is one that  is not already desc ribed in the Inve stigator 
Brochure. 
 
Such reports are to be telephoned or faxed to the F DA within [ADDRESS_1007649] learning of the event. Each telephone ca ll or fax transmission (see fa x 
number be low) should be dir ected to the F DA new drug re view division in the Ce nter for Drug 
Evaluation and Research or in the pro duct review division for the Cent er for Biologics 
Evaluation and Research, whichever is responsible for the review of the IND. 
 
15 Calendar -Day Written Repo rt: 
The Sponsor-Inve stigator is also required to notify the FDA and all participating investigators, in 
a written IND Safety Report, of any serious, unexpected AE that is considered possibly re lated to 
the use of Alisertib. An unexpected adverse eve nt is one that is not already desc ribed in the 
Investigator Brochure. 
 
 
34 
Protocol #13P.528, v5.4 (13September 2017) Written IND Safety Repor ts should include an Analy sis of Sim ilar Events in accordance with  
regulation 21 CFR § 312.32. All safety reports previously filed with the IN D concerning similar 
events should be analy zed. The new report should contain comments on the sig nificance of the 
new event in light of the pre vious, simila r reports. 
 
Written IND safety repor ts with An alysis of Sim ilar Events are to be submitted to the FDA, 
Millennium, and a ll participating investiga tors within [ADDRESS_1007650] learning of the 
event. The F DA prefers these reports on a Me dWatch 3500A Form but al ternative for mats are 
acceptable (e.g. summary letter). 
 
FDA fax number for IN D Safety Reports: 
 
1 (800) FDA - [ADDRESS_1007651] also be 
faxed to: 
 
Millennium Pharmacov igilance 
SAE and Pregnancy R eporting Contact [CONTACT_7171]: 
North America 
[COMPANY_003], Inc. 
Safety and Med ical Manageme nt, US 
Fax:  +[PHONE_3351]  
Hotline number (available 24/7) :  [PHONE_342] 
 
AND 
 
Thomas Jefferson Univer sity IRB 
 
Procedures for Reporting Drug Exposure during P regnancy and B irth Events 
If a woman becomes pregnant or susp ects that she is pregnant while pa rticipating in this s tudy, 
she must infor m the investiga tor immedia tely and must pe rmanently discontinue stu dy drug(s ). 
All pregnancies and suspected pregnancies must be reported to Millennium Pha rmacovigilanc e 
(or designee ) immediately. The p regnancy must be  followed for the final pregnancy outc ome 
(i.e., delivery, sti ll birth, misc arriage) and Millennium Pha rmacovigilance will request this 
information from the in vestigator. 
 
If a female partner of a male patient becomes pregnant during the ma le patient’s participation in 
this study, thi s must be reported to Millennium Pha rmacovigilance (or designee ) immediately. 
Every effort should be made to follow the pre gnancy for the final pregnancy outcome. 
 
IND Annual Reports 
In accordance with the regulation 21 CFR § 312.32, the Sponsor-Inve stigator shall within [ADDRESS_1007652] submit a brief report of the p rogress of 
the investigation. P lease refer to Code of Federal Regulations, 21 CFR § 312.[ADDRESS_1007653] of the 
elements required for the annua l report.  All IND annua l reports submitted to the F DA by [CONTACT_941] 
 
 
35 
Protocol #13P.528, v5.4 (13September 2017) Sponsor-Inve stigator should be copi[INVESTIGATOR_737588].  Copi[INVESTIGATOR_737589]: 
 
Millennium Pharmacov igilance 
 
8.5.2 Data and Safe ty Monitoring Committee 
Data and Safety Monitoring Commit tee (DSMC) is the Data and Safety Monitoring Boa rd 
(DSMB) for the KCC. The DSMC is a multidisciplinary commit tee charged with overs eeing the 
monitoring of safety of participants in clinica l trials, and the conduct, progress, validity, and 
integrity of the da ta for all clinical trials at the Thomas Jefferson Univer sity KCC. The 
committee meets quarte rly to review the progress and safety of a ll active research protocols that 
are not monitored by [CONTACT_737612]. 
• The DSMC me ets quarterly. Additiona l DSMC meetings are scheduled based on the 
nature and numbe r of trials being monitored ove r a specified time period. The DSMC 
meets (by [CONTACT_737613] l) within 24 hours following the notifi cation of an unexpected 
adverse event felt to be re lated to the stu dy drug. 
• Prior to each  DSMC me eting, each boa rd member, is provided a printout of a ll reported 
AEs and SAEs occurring during the reporting period for th is clinical trial. The principal 
investigator [INVESTIGATOR_23897] a detailed and comprehensive narrative a ssessment of  current 
adverse events to da te, indicating their possible significance and whethe r these toxicities 
have affected the conduct of the trial. DSMC members are provided with the principal 
investigator’s a ssessment, a written report summarizing adve rse events, sa fety data, and 
activity da ta observed du ring the specified time period desc ribed in each protocol, a s well 
as recommendations fro m the Medical Monitor. A review of outcome results (response, 
toxicity and adve rse events) and factors external to the study (such a s scientific or 
therapeut
ic development s) is discussed, and the Commit tee votes on the status of each 
study. 
• A summar y of the board’s action is sent to each inve stigator, the CCRRC and TJU IRB s. 
The DSMC actions may include recommendations and/or re quirements that will lead to 
improved patient sa fety and/or efficacy, sig nificant benefits or risks that h ave developed, 
or other change s determined to be n ecessary. The DSMC m ay also take note of slow 
accrual or lack of scientific progress, and refe r such issues to the CCRR C. The DSMC 
provides the investig ator with the rationale for any decis ion made. 
 
8.[ADDRESS_1007654].  Individuals who 
identify a potential produc t complaint situation should imme diately contac t MedComm Solutions 
(see below) and report the event.  Whenever possible, the a ssociated product should be 
maintained in accordance with the label instructions pending fu rther guidance f rom a Millennium 
Quality repre sentative. 
 
For Produc t Complaints, 
call MedComm Solut ions at 
[PHONE_3715] (877 MPI [INVESTIGATOR_53308] ) 
(US and Internationa l) 
 
 
36 
Protocol #13P.528, v5.4 (13September 2017)  
Product complaints in and of thems elves are not AEs. If a product complaint re sults in an SAE, 
an SAE form should be comple ted and sent to [COMPANY_003] (refer to Section 8.2). 
 
9.[ADDRESS_1007655] of 1996 (HIPAA ). 
Those regulations re quire a signed subj ect authorization informing the subject of the foll owing: 
• What protec ted health infor mation (P HI) will be collected from subjec ts in this study 
• Who will have access to that information and why  
• Who will use or disclose that info rmation 
• The rights of a research subjec t to revoke thei r authorization for use  of their PHI. 
 
In the event tha t a subject revokes authorization to collect or use P HI, the inve stigator, by 
[CONTACT_5151], re tains the ability to use a ll information collected prior to the revocation of subj ect 
authorization.  For subjec ts that have re voked authorization to collect or use PHI, atte mpts 
should be made to obtain permi ss ion to collec t at least vital status (i.e. tha t the subject is alive) at 
the end of their  scheduled study period. 
 
9.2 Source Documents 
Source da ta is all information, orig inal records of clinica l findings, observations, or other 
activities in a clinical tri al necessary for the recons truction and evaluation o f the trial. Sourc e 
data are contained in source documents. Exa mples of these original documents, and da ta records 
include: hospi[INVESTIGATOR_17399] l records, clinical and of fice charts, laboratory notes, memoranda, subjec ts’ 
diaries or evaluation checkli sts, pharmacy dispensing records, r ecorded da ta from automated 
instruments, copie s or transcriptions certified after verification as being accurate and comple te, 
microfiches, photographic negatives, microfilm or magnet ic media, x-ray s, subject files, and 
records kept at the pha rmacy, at the laboratories, and at medico-technical departments involved 
in the clinica l trial. 
 
9.3 Case Report Forms 
The study case report form (CRF) is the primary da ta collection instrument fo r the study. All 
data requested on the CRF  must be recorded. All missing data must be  explained. If a space on 
the CRF is left blank because the procedure wa s not done or the que stion was not asked, writ e 
“N/D”. If the item is not applic able to the individ ual case, write “N/A”. All entries should be 
printed legibly in black ink. If any entry er ror has been mad e, to correct such an erro r, draw a 
single straight line through the incorrec t entry and enter the correct data above it. All such 
changes must be initialed and dated. DO NO T ERASE OR WHITE OUT ERRORS. F or 
clarification of il legible or uncertain entr ies, print the clarification above the item, then initial and 
date it. 
 
Please see Appendix VI for CRF. 
 
9.4 Records Retention 
It is the investigator’s responsibility to retain study essential documents for a t least 2 years after 
 
 
37 
Protocol #13P.528, v5.4 (13September 2017) the last approval of a ma rketing appl ication in the ir country and unti l there are no pending or 
contemplated marketi ng applications in their country or a t least [ADDRESS_1007656]. The se documents 
should be re tained for a longer period if required by [CONTACT_737614]. In such an 
instance, it is the responsibility of the sponsor to inform the investig ator/institution as to when 
these documents no longe r need to be re tained. 
 
10.0 STUDY MONITORING, AUDIT ING AND INSPECTING 
10.1 Study Monitoring Plan  
The investigator will allocate adequate time fo r monitoring activities. The Investigator will also 
ensure that the medi cal monitor or other compliance or q uality assurance revie wer is given 
access to all  the above noted study-related documents and study re lated facilities (e.g. pharmacy, 
diagnostic labora tory, etc.), and ha s adequate space to conduct the monitoring visi t. 
 
KCC Investigator Init iated Phase I Studies 
Phase I studies require continuous monitoring by [CONTACT_978] o f the study with quar terly safety and 
monitoring reports submitted to the CRMO and the DSMC. E ach protocol i s assigned to a 
medical monitor (a  member of the Jefferson DSMC who is not dir ectly involved in thi s trial, and 
who is a full voting member of the Jefferson DSMC ). The medical monitor revie ws all adverse 
events (in addition to unex pected adverse events), safety da ta and activity data observed in t he 
ongoing clinica l trial at each new dose level, prior to dose es calation. 
 
The PI [INVESTIGATOR_392288] s a report to the DSMC of all AE/SAEs, safety and tox icity data, and any 
corrective action that occurred on a qua rterly basis. The medical monitor also provide s a 
summary o f their review. The summary of all discussions of adve rse events are submitted to t he 
DSMC, and these re ports are reviewed during the DSMC me etings that take place qua rterly. 
Patients are only identified by [CONTACT_10573], and no othe r personal health information (PHI ) is includ ed 
in the reports. 
 
The medical monitor may r ecommend reporting adve rse events and re levant safety data not 
previously re ported, and may r ecommend suspension or te rmination of the trial based on their 
review of AE/SAE data observed throughout t he life of a clinical trial. In such c ircumstances, 
and “ad hoc” DSMC me eting will be called to disc uss corrective action with the PI. If f or any 
reason the PI [INVESTIGATOR_737590], the 
issue will be re ferred to the Asso ciate Director of Clinical Inve stigations, who will be 
responsible for dispute re solution. 
 
The summary of all discussions of adve rse events are included in the KCC  investigator’s re ports 
to the TJU IRB s as part of its annual progre ss report. The DSMC and the TJU IRB s may, based 
on the monitor ’s recommendation, suspend or te rminate the trial. The  quarterly safety and 
monitoring reports include a stat ement as to whethe r this data  has invoked any stoppi[INVESTIGATOR_007] c riteria 
in the clinical protocol. 
 
10.2 Aud iting and Insp ecting 
The investigator will permit study-related monitoring, audits, and inspections of a ll study related 
documents (e.g. source documents, reg ulatory documents, da ta collection instruments, study da ta 
 
 
38 
Protocol #13P.528, v5.4 (13September 2017) etc.) by [CONTACT_1201], the funding sponsor, gove rnment regulatory bodies, and Univer sity compliance 
and quality a ssurance groups. The investigato r will ensure the capability for inspections of 
applicable study-related facilities (e.g. pharmacy, diagnostic labora tory, etc.). 
 
Participation as an investiga tor in this study implie s acceptance of potential inspection b y 
government regula tory authorities and applicable University compliance and quality a ssurance 
offices. 
 
10.2.[ADDRESS_1007657] achieved 10% of t arget accrual. Howeve r, a study can be 
audited at any time based on recommendations by [CONTACT_1201], DSMC, CCRR C and/or the Dir ector 
of Clinical Inve stigations, KCC. Studie s are re-audited once th ey have ac hieved 50% of target 
accrual. Special audits may be recommended by [CONTACT_1201] , DSMC or CCRRC b ased on pr ior 
findings, allegations of sc ientific misconduc t and where significant irregula rities are found 
through quality control p rocedures. Any irregularities identified as par t of this process would 
result in a full audit of th at study. 
 
In addition to the audits at 10% and 50%, the CR MO randomly audit s at least [ADDRESS_1007658] a bi-annual 
basis, to verify that there is a signed and da ted patient conse nt form, the patie nt has met the 
eligibility criteria, and that SAEs are documented and reported to the TJU IRB. 
 
All audit r eports are submitted to the DS MC for review and action (when appropri ate). A copy of 
this report and recom mended DSMC action is se nt to the CCRR C and TJU IRB . The committee 
regards the sc ientific review process as dynamic and constructive ra ther than punitive. The 
review process is designed to assi st Principal Investigators in ensuring the safety of study 
subjects and the adequacy and accuracy of any data generated. The TJU IRB may, based on the 
DSMC and auditor ’s recommendation, suspend or te rminate the trial. 
 
11.0 Ethical Consid erations 
This study is to be conduc ted according to US and international standards of Good Clinical 
Practice (F DA Title 21 part 312 and Inte rnational Conference on Harmonization guidelines), 
applicable gove rnment regulations and Insti tutional research polic ies and procedure s. 
 
This protocol and any ame ndments will be submit ted to a properly constituted independent 
Institutional Review Board (IRB), in agr eement with local legal prescriptions, for for mal 
approval of the stu dy conduct.  The decis ion of the IRB con cerning the conduct of the stu dy will 
be made in writing to t he investiga tor before commencement of th is study. 
 
All subjects for this study will be pro vided a consent form that is complia nt with local and federa l 
regulations, descr ibing this study and providing sufficient information for subj ects to make an 
informed decis ion about the ir participation in this s tudy. See Attachment for a copy of the 
Subject Informed Consent Form. This consent for m will be submitte d with the protoc ol for 
review and approva l by [CONTACT_737615] r the study. The for mal consent of a subj ect, using the IRB- 
approved conse nt form, must be obtained be fore that subj ect is submitted to any study procedure. 
 
 
39 
Protocol #13P.528, v5.4 (13September 2017) This conse nt form must be signed by [CONTACT_737616], and the 
investigator-designa ted research profe ssional obta ining the consent. 
 
12.[ADDRESS_1007659] with this study (patent ownership, royalt ies, or 
financial gain greater than the min imum allowable by [CONTACT_737617], e tc.) must have the 
conflict reviewed by a properly constituted Conflict of Intere st Committee with a Committee- 
sanctioned conflic t management plan that ha s been reviewed and approved by [CONTACT_737618] s tudy. All Jefferson University Investigators will follow the TJ U 
Conflicts of Intere st Policy for Employees (107.03). 
 
12.[ADDRESS_1007660] receive copi[INVESTIGATOR_737591] p ublication (a t least fifteen working day s for 
presentational mate rials and abstracts and thirty working days for manuscripts). The se 
requirements acknowledge Mil lennium’ responsibility to provide pee r input rega rding the 
scientific content and conclusions of such publications or pre sentations. P rincipal 
Investigation/Insti tution shall have the final authority to dete rmine the scope and content of it s 
publications, provided such authority sha ll be exerc ised with reasonable regard for the intere sts 
of Mill ennium and, in accord with the trial contract and sha ll not permi t disclosure of 
Millennium confidentia l or proprietary information. 
 
Neither the complete nor any pa rt of the result s of the study carried out under this protocol, nor 
any of the information provided by [CONTACT_78265] r for the purposes of performing the study, will be 
published or passed on to any third party without the consent of the stu dy sponsor. An y 
investigator involve d with this study is obligated to provide the sponsor with comple te test 
results and all data derived from the stu dy. 
 
14.0 REF ERENCES 
1. Siegel, R., et al., Can cer statistics, 2011: the impac t of eliminating socioeconomic and 
racial disparities on p remature cancer deaths. CA Cancer J Clin, 2011. 61(4): p. 212-36. 
2. Stupp, R., et al., Radiotherapy plus concomi tant and adjuvant temozolomide f or 
glioblastoma . N Engl J Med, 2005. 352(10): p. 987-96. 
3. Stupp, R., et al., Effec ts of  radiotherapy with concomitant and adjuvant te mozolomide 
versus radiotherapy a lone on surviva l in glioblastoma in a ra ndomised pha se III study: 5- 
year analysis of the EORTC-NCI C trial. Lancet Oncol, 2009. 10(5): p. 459-66. 
4. Da r, A.A., et al., Auro ra kinase inhibitors --rising stars in cance r therapeutics? Mol 
Cancer Ther, 2010. 9(2): p. 268-78. 
 
 
40 
Protocol #13P.528, v5.4 (13September 2017) 5. Temme, A., et al., Giant cell glioblastoma is asso ciated with alte red aurora b expre ssion 
and concomitant p53 mutation. J Neuropa thol Exp Neurol, 2010. 69(6): p. 632-42. 
6. Bie, L., et al., Kinesin family member 2C (KIF2C /MCAK) is a novel marker for 
prognosis in human glio mas. Clin Neurol Neurosurg, 2012. 114(4): p. 356-60. 
7. Tao, Y., et al., Enhancement of ra diation response by [CONTACT_737619]- A kinase using 
siRNA or a selective Au rora kinase inhibitor PHA680632 in p53-de ficient cancer cells. 
Br J Cancer, 2007. 97(1 2): p. 1664-72. 
8. Lehman, N.L., et al., Aurora A is dif ferentially expre ssed in gliomas, is asso ciated with 
patient survival in glioblastoma and is a potential che motherapeutic ta rget in gliomas. 
Cell Cycle, 2012. 11(3): p. 489-502. 
9. Manfredi, M.G., et al., Characte rization of Alise rtib (MLN8237 ), an investigationa l 
small-molecule inhibitor of aurora A kin ase using novel in vivo phar macodynami c 
assays. Cli n Cancer R es, 2011. 17(24): p. 7614-24. 
10. Carol, H., e t al., Efficacy and pharmac okinetic/p harmacodynamic evaluati on of the 
Aurora kinase A inhibitor MLN8237 against pr eclinical models of pediatric cancer. 
Cancer Ch emother Pharmacol, 2011. 68(5): p. 1291-304. 
11. Choe, G., et al., Analy sis of the phosphatidylinositol 3'-kinase si gnaling pathway in 
glioblastoma patients i n vivo. Cancer R es, 2003. 63(11): p. 2742-6. 
12. Er moian, R.P., et al., Dys regulation of PTEN and protein kinase B is associated with 
glioma histolo gy and patient survival. Cli n Cancer Res, 2002. 8(5): p. 1100-6. 
13. Short, S.C., et al., DN A repair after irradiation in gli oma cells and normal human 
astrocytes. Neuro Oncol, 2007. 9(4 ): p. 404-11. 
14. Brem, S.S., P.M. Gullino, and D. Medina, Angiogene sis: a marker for neoplastic 
transformation of mammary papil lary hyperplasi a. Science, 1977. 195(4281): p. 880-2. 
15. Nagarajan, R .P. and J.F. Costello, Epi[INVESTIGATOR_737592]. 
Semin Cancer Biol, 2009. 19(3): p. 188-97. 
16. Leighton, C., et al., Supra tentorial low-grade glio ma in adults: an analysis of prognostic 
factors and timing of radiation. J Cli n Oncol, 1997. 15(4): p. 1294-301. 
17. Huang, Q., e t al., Glio ma stem cells are more aggressive in recurrent tumors with 
malignant prog ression than in the primary tumor, and both can be ma intained long-te rm 
in vitro. B MC Cancer, 2 008. 8: p. 304. 
18. McCormack, B.M., e t al., Treatment and su rvival of low-grade a strocytoma in adults -- 
1977-1988. Neurosurgery, 1992. 31 (4): p. 636-42 ; discussion 642. 
19. Carson, K.A., et al., Prognostic factors for survival in adult patie nts with r ecurrent gli oma 
enrolled onto the new approaches to brain tumor therapy CNS consortium pha se I and II 
clinical trials. J Clin Oncol, 2007. 25(18): p. 2601-6. 
20. Young, B., et al., Reoperation for glioblastoma . J Neurosurg, 1981. 55(6): p. 917-21. 
21. Harsh, G.R.t., et al., Reoperation for recur rent glioblastoma and ana plastic astrocytoma. 
Neurosurgery, 1987. 21 (5): p. 615-21. 
22. Ammirati, M., et al., Reoperation in the tr eatment of recur rent intracra nial malignant 
gliomas. Ne urosurgery, 1987. 21(5): p. 607-14. 
23. Hudes, R.S., et al., A pha se I dose escalation stu dy of hypofractiona ted stereotactic 
radiotherapy a s salvage therapy for persistent or recurrent malignant gli oma. Int J Radiat 
Oncol Biol Phys, 1999. 43(2): p. 293-8. 
24. Combs, S.E., et al., Ef ficacy of fractionated stereo tactic reirradiation i n recurrent 
gliomas: long -term results in 172 patients trea ted in a single institution. J Clin Oncol, 
 
 
41 
Protocol #13P.528, v5.4 (13September 2017) 2005. 23(34 ): p. 8863-9. 
25. Fokas, E., et al., Hypof ractionated stereotactic reirradiation of recurrent glioblastoma s : a 
beneficial treatment option af ter high-dose ra diotherapy? S trahlenther Onkol, 2009. 
185(4): p. 235-40. 
26. Patel, M., et al., Sa lvage reirradiation for recurrent glioblastoma with r adiosurgery: 
radiographic response and improved survival. J Neurooncol, 2009. 92(2): p. 185-91. 
27. Cho, K.H., et al., S ingle dose versus fractionated stereotactic radiotherapy for recurrent 
high-grade gli omas. Int J Radiat Oncol Biol Phy s, 1999. 45(5 ): p. 1133-41. 
28. Combs, S.E., et al., S tereotactic radiosurgery (SRS ): treatment option for r ecurrent 
glioblastoma mu ltiforme (GBM). Cancer, 2005. 104(10): p. 2168-73. 
29. Fogh, S.E., et al., Hypo fractionated stereotactic radiation therapy: an effective the rapy for 
recurrent high-gra de gliomas. J Clin Oncol, 2010. 28(18): p. 3048-53. 
30. van den Bent, M.J., e t a l., Randomized phase II trial of erlotinib ver sus temozolomide or 
carmustine in recurre nt gliobla stoma: EORTC  brain tumor group study [ZIP_CODE]. J Clin 
Oncol, 2009. 27(8 ): p. 1268-74. 
31. Kappelle, A.C., et al., PC V chemotherapy for recur rent glioblastoma mu ltiforme. 
Neurology, 2001. 56 (1): p. 118-20. 
32. Schmidt, F., et al., P CV chemotherapy fo r recurrent glioblastoma. Neurology, 2006. 
66(4): p. 587-9. 
33. Vredenburgh, J.J., et al., Bevacizumab plus irinot ecan in recurrent glioblast oma 
multiforme. J Clin Oncol, 2007. 25(30): p. 4722- 9. 
34. Zuniga, R.M., et al., Effi cacy, safety and patte rns of response and re currence in patients 
with recurrent high-grade gli omas treated with bevacizumab plus irinot ecan. J 
Neurooncol, 2009. 91(3):  p. 329-36. 
35. Kreisl, T.N ., et al., Pha se II trial of single-agent bevacizumab followed by [CONTACT_737620]. J Clin Oncol, 2009. 27(5): 
p. 740-5. 
36. Sore nsen, A.G., et al., A "vasc ular normalization index" as potentia l mechanistic 
biomarker to predict survival after a single dose of cediranib in r ecurrent glioblastoma 
patients. Cancer R es, 2009. 69(13 ): p. 5296-300. 
37. Ba tchelor, T.T., et al., AZD2171, a pan- VEGF receptor tyrosine kinase inh ibitor, 
normalizes tumor vasculature and alle viates edema in glioblastoma patients. Cancer C ell, 
2007. 11(1 ): p. 83-95. 
38. Friedman, H.S., et al., Be vacizumab alone and in combination with irinot ecan in 
recurrent glioblastoma . J Clin Oncol, 2009. 27(28): p. 4733-40. 
39. Iwa moto, F.M., et al., Patterns of re lapse and prognosis af ter bevacizumab failure in 
recurrent glioblastoma. Neurology, 2009. 73 (15): p. 1200-6. 
40. Arcicasa, M., et  al., Reirradiation and lomustine in patients with r elapsed high-g rade 
gliomas. Int J Radiat Oncol Biol Phys, 1999. 43(4): p. 789-93. 
41. Larson, D.A., et al., Pha se II study of high central dose Gamma Kni fe radiosurgery and 
marimastat in patients with r ecurrent malignant gli oma. Int J Radiat Oncol Biol Phy s, 
2002. 54(5 ): p. 1397-404. 
42. Nigg, E.A., Mitotic kinases as regulators of cell division and its checkpoints. Na ture 
Reviews Molecular Cell Biology, 2001. 2 (1): p. 21-32. 
43. Bischoff, J.R., et al., A homolog ue of Drosophila aurora kina se is oncogenic and 
amplified in human color ectal cancers. EMBO Journal, 1998. 17(11): p. 3052-65. 
 
 
42 
Protocol #13P.528, v5.4 (13September 2017) 44. Sen, S., et al., Ampli fication/ove rexpression of a mi totic kinase gene in human bladder 
cancer. Journal of the Nationa l Cancer Insti tute, 2002. 94(17): p. 1320-9. 
45. Ca macho, E., et al., Analys is of Aurora-A and hMPS1 mitotic kinases in mantle cell 
lymphoma. Inte rnational Journa l of Cancer, 2006. 118(2): p. 357-63. 
46. Ikezoe, T., et al., A nove l treatment strat egy targeting Aurora kinases in acu te 
myelogenous leukemia. Mol ecular Cancer Therapeutics, 2007. 6(6): p. 1851-7. 
47. Chng, W.J., et al., Clin ical implication of centro some amplification in pla sma cell 
neoplasm. Blood, 2006. 107(9): p. 3669-75. 
48. Kataya ma, H., W.R. B rinkley, and S. Sen, The Au rora kinases: role in cell tra nsformation 
and tumorigene sis. Cancer & Metastasis Review s, 2003. 22(4): p. 451-64. 
49. Marumoto, T ., et al., Aurora- A kinase maintains the fidelity of early and la te mitotic 
events in HeLa cells. Journa l of Biological Chemistry, 2003. 278(51): p. [ZIP_CODE]-95. 
50. Glover, D.M., et al., Mutations in aurora prevent centrosome separation leading to t he 
formation of monopolar spi[INVESTIGATOR_36874]. Cell, 1995. 81(1): p. 95-105. 
51. Kataya ma, H., et al., Interaction and f eedback regulation betw een STK15/BTAK/Aurora- 
A kinase and protein phospha tase 1 through mi totic cell division cyc le. Journal of 
Biological Chemistry, 2001. 276(49): p. [ZIP_CODE]-24. 
52. Hoar, K., et al., ML N8054, a smal l-molecule inhibitor of Au rora A, causes spi[INVESTIGATOR_737593]. Mol ecular & Cell ular 
Biology, 2007. 27 (12): p. 4513-25. 
53. Maris, J.M., e t al., Initial testing  of the aurora kina se A inhibitor MLN8237 by [CONTACT_737621] l T esting Program (PPTP). Pediatr Blood Cancer, 2010. 55(1): p. 26- 
34. 
54. Gorgun, G., et al., A nove l Aurora-A kinase inhibitor MLN8237 induce s cytotoxicity and 
cell-cycle arre st in multiple myeloma. Blood, 2010. 115(25): p. 5202-13. 
55. Borge s, K.S., et al., Inhibition of Aurora kinases enhances c hemosensit ivity to 
temozolomide and cause s radiosensitization in glioblastoma cell s. J Cancer R es Clin 
Oncol, 2012. 138(3 ): p. 405-14. 
56. Venka taraman, S., et al., Targ eting Aurora Kinase A enhances radiation sensit ivity of 
atypi[INVESTIGATOR_737594]. J Neurooncol, 2012. 107(3): p. 517-26. 
57. Honda, R., R . Körner, and E.A. Nigg, Exploring the functiona l interactions be tween 
Aurora B, INCENP, and  survivin in mitosis. Mol Biol Cell, 2003. 14(8): p. 3325-41. 
58. Giet, R., et al., Drosophila Aurora A kin ase i s required to local ize D-TACC to 
centrosomes and to regula te astral microtubules. J Ce ll Biol, 2002. 156(3): p. 437-51. 
59. Quant, E.C. and P.Y. Wen, Response a ssessment in neuro-oncology. Curr Oncol Rep, 
2011. 13(1 ): p. 50-6. 
60. Wen, P.Y., et al., Updated response asse ssment crite ria for high-gra de gliomas: response 
assessment in neu ro-oncology working group. J Cl in Oncol, 2010. 28(11): p. 1963-72. 
 
15.0 Appe ndices 
Appendix I ECOG Pe rformance status sca le 
 
Appendix II Visit Schedule 
 
Appendix III SAE form 
 
 
43 
Protocol #13P.528, v5.4 (13September 2017) Appendix IV MMSE 
 
Appendix V QoL forms  
 
Appendix VI Ca se Report Forms 
 
 
 
Appendix I: ECOG  Performance Sta tus 
 
Grade Descriptions  
0 Normal activity. Fully  active, able to carry on all pre-disease performance 
without restriction. 
1 Symptoms, but ambulatory. Restricted in physically  strenuou s activity, but 
ambulatory and ab le to carry out wo rk of a light o r sedenta ry nature (e.g., light 
housework, office work). 
2 In bed <50% of the time. Ambulatory and capable of all self-care, but unable to 
carry out any work acti vities. Up and about more than 50% of waking hours. 
3 In bed >50% of the time. Capable of only limited self-care, confined to bed or 
chair more  than 50% of waking hours. 
4 100% bedridden. Completely disabled. Cannot carry on any self- care. Totally 
confined to bed or chair. 
5 Dead 
 
 
44 
Protocol #13P.528, v5.4 (13September 2017)  
  
 
  
 
 
Appendix II: Visit Sch edule 
 
 Prior to 
Registr ation Pre- 
treatment Concurrent 
phase Observation 
phase Maintena nce 
phase Recommended 
Follow up 
Time (day) -14 to -1 -30 to -1 1-7 8-14 Day 13-42 From Day 43 
to 1 year Year 2 and 
onwards 
Informed 
consent  X       
Demographics X       
Medical history X X      
H & P X X X7 X7 X5 Q 2 months X6 
Neuro exam X X X8 X7 X5 Q 2 months X6 
MMSE  X   X5 Q 2 months X6 
QoL  X   X5 Q 2 months X6 
Vitals  X X7 X7 X5 Q 2 months X6 
Weight  X X7 X7 X5 Q 2 months X6 
KP/ECOG X X X X7 X5 Q 2 months X6 
CBC w diff X X X7 X7 X5 Weekly8 X6 
CMP, Mg + X X X8 X7 X5 Q 2 months X6 
PT/PTT/INR  X      
Lipid Panel   X7 X7 X5 Q 2 months  
EKG   X      
b-HCG  X9       
MRI Brain  X   X1 Q 2 months X6 
Treatment:        
RT   X2 X2    
MLN8237   X3 X3  X4  
Q = every 
H & P  = History & Physi cal 
 
NOTE: 
1. Brain MRI shoul d be done betwee n days 35-[ADDRESS_1007661] year. 
2. RT: daily on weekdays for a tot al of 10 treatments. 
3. Aliser tib: BID on days of RT o nly. 
4. Aliser tib: 50 m g BID on days 1- 7 every 21 day s, for up to 18 cycl es or  until progression. 
5. Between day  39 to day 45 (at the end of 30 day ob servation period), th en ev ery [ADDRESS_1007662] should be do ne withi n 7 days pri or to regis tration, if app licable 
 
 
45 
Protocol #13P.528, v5.4 (13September 2017)  
 
Appendix III: SAE FORM 
 
 
 
46 
Protocol #13P.528, v5.34(13September 2017)  
 

 
47 
Protocol #13P.528, v5.4 (13September 2017  
 

 
48 
Protocol #13P.528, v5.4 (13September 2017 
Appendix IV: MMSE 
 
 
 
Appendix V: QoL forms 
49 
Protocol #13P.528, v5.4 (13September 2017  
 
 
50 
Protocol #13P.528, v5.4 (13September 2017  
 

 
51 
Protocol #13P.528, v5.4 (13September 2017  
 

 
52 
Protocol #13P.528, v5.4 (13September 2017  
Appendix VI: Case Report Form  
 
SCREENING  
 
 
VISIT DATE  :    
 
 
Date Scre ening  Informed 
Consent Signed:    
Not Applicable  Screening  Date : 
Not Applicable  
Is this participant a scr een failu re? Yes No (If Yes, complete Off Study form) 
If yes, specify pr imary reason fo r screen failu re: Investigato r decision 
Participant decis ion 
Did not meet el igibili ty criteria 
Other, specify : 
Com ments: 
Who referred partic ipant? Physician 
Health Care Provider 
Family/friend 
Self 
Other, specify: 
 
 
How did partic ipant find out a bout the st udy? Phy sician Nurse 
Family/frien d 
NCI web site 
Written material 
Unknown 
Other, specify: 
 
 
INCLUSION CRITERIA  
53 
Protocol #13P.528, v5.4 (13September 2017)  
 Criteria Yes No N/A 
 
 
[ADDRESS_1007663] a previously histologically or cytologically confirmed high grade 
glioma (as trocytic or oligodendrog lial su pratent orial tumors grade 3 or 4) that has be en 
previously treated with fr actionated radiation therapy an d now  shows evidence of 
recurrence.    
[ADDRESS_1007664] a 2 week break between prior treatment and the protocol treatment.    
 
5 Prior treatment with fractionated radiation therapy (up to 60Gy) is an eligibility criterion, 
howev er there shoul d not hav e been a second co urse o f fraction ated ra diotherapy to 
the su pratentorial area.    
 
6 One prior single fraction radiosurgical proce dure within the treatment field is acceptable 
if V12 <5 cc (V 12 is the vol ume of norm al brain (outside GTV ) receiving 12 or more Gy) . 
Additional radiosurgical proced ures outside of the treatment area  are acceptable.    
 
[ADDRESS_1007665] is required for 2 
hours before and 1 hour after MLN8237 administration.    
 
 
8 ANC > 1500/mm³, platelets >  100,000/mm³, Hgb > 9 g/dL. Values must be obtained 
without need fo r myeloi d growth fact or or platelet transf usion support withi n 14 days o f 
registr ation , howev er, erythrocyte growth f actor is a llowed as per  published ASCO 
guidelines.    
 
9 Total bilirubin ≤ U LN, SGOT (AST) and SGPT (ALT)< 1.[ADDRESS_1007666], within 14 days of 
registration.    
 
10 Adequate renal 
mL/minute (Cockcroft-Gault), within 14 days of registration.    
11 Age >18 years.    
12 ECOG performance status <2 (see Appendix I).    
[ADDRESS_1007667] agree to use  adequate contraception 
(hormon al or barri er metho d of birth con trol; abstine nce) pri or to study e ntry and f or the 
duration of study participation.    
16 Ability to und erstand and the willingness to sign a written informed consent docume nt.    
 

 
54 
Protocol #13P.528, v5.4 (13September 2017) 
EXCLUSION CRITERIA 
 
 Criteria Yes No N/A 
 
2 Known history of uncontrolled sleep apn ea syndrome and  other conditions that could 
result in excessiv e day time sleepi[INVESTIGATOR_008], such  as severe chronic obstr uctive pulmonary 
disease; requirement for supplemen tal oxygen.    
 
[ADDRESS_1007668] 
dose of study drug, or other severe infection.    
 
 
 
4 Myocardial infarction within 6 months prior to enrollment or has [LOCATION_001] Heart 
Associ ation (NYHA ) Class III or IV hear t failure, uncontrolled a ngina , severe 
uncon trolled ventricular arrhythmias, or elec trocardiographic evide nce of acute 
ischemi a or a ctive conducti on system abno rmalities. Prior to study e ntry, any ECG 
abno rmality at Screenin g has  to be document ed by t he investigator as no t medically 
relevant.    
 
 
[ADDRESS_1007669] is not 
pregna nt mus t be e stablished by a negativ e seru m β-hum an chorio nic gonado tropin 
(β-hCG) pregna ncy test result obtained during screening .  Pregna ncy testi ng is no t 
required for post-menopausal or  surgically sterilized women.     
[ADDRESS_1007670] . John's w ort withi n [ADDRESS_1007671] dose of MLN823 7 and 
during the study.    
 
11 Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or 
hepatitis C. Testing is not required in the absence of clinical findings or suspi[INVESTIGATOR_2798].    
 
 
 
[ADDRESS_1007672] a history of any other malignancy from which the patient has been 
disease-fr ee for less than 2 years, wit h the excepti on of adequately treate d basal or 
squamous cel l carci noma of ski n, superfici al bladder cancer o r carci noma i n situ  of 
cervix, AJC C (version 7.0) stag e [ADDRESS_1007673] ca ncer, AJCC (version 7.0) stage I , or II 
prostate cancer.    
 
13 Radiation therapy to more than 25% of the bone marrow. Whole pelvic radiation is 
considered to be over 25%.    
 
 
55 
Protocol #13P.528, v5.4 (13September 2017) 
REGISTRATION  
Gende r: 
Male Female Unknown 
Unspecif ied  
 
Date of Birth:    
Race: White 
(Check all that ap ply) Black  or African 
American 
Native Hawaiian or 
Other Pacif ic Islander 
Asian  
American I ndian or 
Alaska Na tive 
Unknown Ethnicity: Hispanic or Latino 
Not Hispanic or Latino 
Unknown 
Date Study Informed 
Consent Signed:     
 
Date of Registratio n:    
Does the pa rticipant sa tisfy all of the el igibili ty criteria? 
Yes No (If No, co mplete Off Study form) 
 
 
 
56 
Protocol #13P.528, v5.4 (13September 2017) 
INTERVENTION  ADMINISTRATION  
 
 
 
 
 
Agent 
#  
 
Agent  
 
Dose   
Dose  
Units   
 
Frequency Date Agent 
Provided (to 
Participant)  
Date Agent 
Started 
1       
2       
3       
 
 
57 
Protocol #13P.528, v5.4 (13September 2017)  
BASELINE M EDICAL/SURGICAL HISTORY 
 
Check here if a ll body sys tems are normal: 
 
 
Body System  
 
Normal  
 
Abnormal  
Not 
Assessed Com ments 
(Required if A bnormal; provid e 
condition/d iagnos is) 
 
H/E/E/N/T     
 
Neck      
 
Respi[INVESTIGATOR_737595]/Lymph     
 
Endocrine /Metabolic     
 
Genitourinary     
 
Breasts     
 
Neurologic     
 
Does the pa rticipant have any allerg ies? Yes No 
 
If Yes, specify: 
 
 
58 
Protocol #13P.528, v5.4 (13September 2017) 
BASELINE SYM PTOMS  
 
Check here i f none reported (no baseline sympt oms): 
 
 
Symptom Descrip tion  
Onset Da te  
Grade*  
Com ments 
    
    
    
    
    
    
    
    
    
    
    
    
*Grade 
1 = Mild; 2 = Modera te; 3 = Severe; 4 = Life Threatening 
 
 
59 
Protocol #13P.528, v5.4 (13September 2017) 
PHYSICAL EXAM  
 
Examination Date :    Not Done 
Heigh t:    cm 
Not Obtained in Weigh t:    kg 
Not Obtained lb Tempe rature:    °C 
Not Obtained °F 
Pulse Rate:     
Not Obtained Respi[INVESTIGATOR_26452] :     
Not Obtained Blood Press ure:     
Not Ob tained    Systo lic (mm Hg) Diasto lic (mm Hg) 
ECOG  Performan ce Status: 0 1 2 3 4 
Check here i f NO body systems were examined: 
 
 
Body System/ Site  
Normal  
Abnormal Not 
Examined Commen ts 
(Required if A bnormal; provide condition/diagnosis) 
Appea rance*     
Skin*     
H/E/E/N/T*     
Thyroid     
Chest     
Lungs     
Breasts     
Heart     
Abdom en     
Muscu loskeletal*     
Genitalia     
Pelvis     
Rectal     
Prost ate     
Vascu lar     
Neurological*     
Lymph No des     
* Require d Assessments 
All other Body Systems/Sites are to be done a s clinically indi cated. 
 
 
60 
Protocol #13P.528, v5.4 (13September 2017) 
 
MMSE and QLQ result  
 
* Attach MMSE and QLQ result here.  
 
 
61 
Protocol #13P.528, v5.4 (13September 2017) 
 
BASELINE IMAGI NG STUDY PRIOR TO RECEIV ING PROTOCOL  TREATMENT 
(Fill in what is applicable) 
 
 
 
* Please attached MRI, CT, PET/CT report here. 
 
 
62 
Protocol #13P.528, v5.4 (13September 2017) 
 
CONCOMITANT MEDICA TIONS/STEROIDS USE LOG  
(medic ations prescribed during study period) 
 
 
At end of study only: check this box if participant did not take any c oncomitant medications  
None 
 
 
 
Date  
 
Medica tion  
 
Dose   
 
Frequency  
 
Start Da te  
 
Stop Da te  
 
Continuing  
       
       
       
       
       
       
       
       
       
       
       
       
       
       
 
 
63 
Protocol #13P.528, v5.4 (13September 2017) 
 
CLINICAL LABORATORY DATA  
 
* Attached blood test r eport  here.  
* Attach EKG report here.  
 
 
64 
Protocol #13P.528, v5.4 (13September 2017) 
 
PREGNANCY S PECIMEN DATA  
 
 
 
If “participant is male” or “participant is female and not of chi ldbearing poten tial” and p regnancy 
specimen data wa s NOT  COLLECT ED please se lect the corresponding  check-box below. 
Otherwise, if partic ipant is female and is of chi ldbearing poten tial, please co mplete the for m by 
[CONTACT_737622] o r check the “Not Obtained box” if a test was not  
perform ed. 
 
 
Reason p regnancy data was not collected : 
Participant is male 
Participant is fema le and not of chi ldbearing poten tial 
 
 
 
Lab Test  
Pregnancy Test 
Type  
 
Result Date Specimen 
Collec ted 
 
 
Pregnancy  
Urine 
Serum Not Obtaine d 
Positive 
Negative  
 
 
65 
Protocol #13P.528, v5.4 (13September 2017) 
 
TREATMENT INTERR UPTION / MODIFICATIO N FORM  
 
 
TREATME NT Interruptions: 
 
 
Stop Date Reason  Stopp ed Specify Reas on 
Stopped  
 
Investig ator deci sion, specify 
1 Participa nt decisio n, specify 
AE/S AE, specify 
Other, specify 
Investig ator deci sion, specify 
2 Participa nt decisio n, specify 
AE/S AE, specify 
Other, specify 
Investig ator deci sion, specify 
3 Participa nt decisio n, specify 
AE/S AE, specify 
Other, specify 
Investig ator deci sion, specify 
4 Participa nt decisio n, specify 
AE/SAE
, specify 
Other, specify  
Was Age nt 
Restarted? 
 
Yes 
No 
N/A 
 
Yes 
No 
N/A 
 
Yes 
No N/A 
 
Yes 
No 
N/A If Yes, 
date restarted  
 
 
66 
Protocol #13P.528, v5.4 (13September 2017) 
 
AE log 
 
Attached AE log form here 
 
 
67 
Protocol #13P.528, v5.4 (13September 2017) 
 
OFF STUDY* 
 
 
Date On Follow- up: 
 
Not Applicable   
Date Off Follow- up: 
Not Applicable  
 
Date Off Study:  
Date of Last Contact: 
 
[CONTACT_737623] A gent Taken: 
Not Applicable 
 
 
Reason Off  Study  (Please mark only the primary reason. R easons other than Com pleted 
Study require exp lanation be low) 
Completed study 
Ineligible  
 
AE/SAE (complete AE CRF & SAE form, if applicable) 
 
Lost to follow- up 
 
Non-compliant partic ipant 
Concom itant medicatio n 
Medical c ontraindicatio n 
Pregnancy 
Withd raw consent 
 
Death (complete Deat h Report CRF & SAE f orm) 
 
Other 
 
Reason Exp lanation: 
 
 
  
 
  
 
*This form must be co mpleted fo r all participants that have sig ned an informed consen t, 
including  screen failures. 
 
 
68 
Protocol #13P.528, v5.4 (13September 2017) 
 
DEATH REPORT  
 
 
 
 
Date of Death:    
Place of Deat h: 
 
Hospi[INVESTIGATOR_307] (Sub mit disc harge summary to NCI, 
DCP) 
 
Other, sp ecify: 
 
 
Unknown Cause of Death: 
 
 
AE/SAE 
 
Other, sp ecify:    
 
Unknown 
 
Autopsy  perfo rmed? Y es (Attache d autopsy rep ort here) 
No 
Unknown 
 
 
69 
Protocol #13P.528, v5.4 (13September 2017) 
 
VERIFICATION  
 
 
 
 
The Investigat or signa ture on this for m should be obtained af ter ALL the Case Report Forms f or this 
participant have be en completed. 
  
 
“I have reviewed all the Case Report For ms for the above participant and agree that they 
are accurat e and complete.” 
   
 
 
 
Investigator’s S ignature Date 
 
   
 
 
Investigator Name (PLE ASE PR INT) 
 